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ABSTRACT 
THE EFFECTS OF NICOTINE AND CIGARETTE SMOKING ON CARDIAC 
ELECTROPHYSIOLOGY 
Affan B. Irfan 
November 27, 2019 
Cigarette smoking is a leading cause of preventable disease and premature death 
worldwide. The adverse effects of cigarette smoking, including proarrhythmia, are related 
to the mixture of chemicals, including nicotine (which sustains tobacco addiction). 
However, it remains unclear which individual tobacco smoke constituents and biological 
pathways mediate this increased risk. The purpose of this research was to explore the 
chronic effects of cigarette smoking, as well as compare the acute effects of nicotine and 
cigarette smoking, and the possible role of β-adrenoreceptors, on human cardiac 
electrophysiology. Chapter 1 is a comprehensive literature review of (a) the ex vivo and in 
vivo effects of nicotine and non-nicotine constituents of cigarette smoking on cardiac ion 
channels, (b) the direct and indirect effects of the autonomic nervous system on cardiac 
electrophysiology, and (c) studies of acute and chronic effects of cigarette smoking in 
humans. Chapter 2 consists of two studies in which we used cotinine levels to investigate 
the differences in baseline cardiac electrocardiogram between chronic smokers and non-
smokers, and to define smoking status and its burden. We also explored the relationship 
between urinary catecholamines, cotinine, and electrocardiographic changes. Chapter 3 
features the 2 x 2 factorial experimental study designed to compare
vi 
the acute effects of cigarette smoking and nicotine, with and without a β-blocker 
(propranolol). We found that chronic cigarette smoking was associated with a shortened 
PR segment at baseline, and that dopamine possibly mediates this effect. There was also 
(corrected) QT interval shortening with increased cotinine levels. This experimental study 
revealed that the non-nicotine constituents in cigarette smoking were mainly responsible 
for PR segment shortening, through β-adrenoreceptors. Other evidence revealed that, 
although nicotine in cigarette smoke is primarily responsible for sympathetic activation 
and (corrected) QT interval shortening, it is the non-nicotine constituents that depress the 
ST segment. Collectively, acute and chronic exposure studies indicate that smoking may 
promote cardiac arrhythmia, primarily via β-adrenoreceptors, causing acceleration of 
dromotropy and ischemia (non-nicotine mediated), and ventricular repolarization 
(nicotine-mediated). This research elucidated a major physiological mechanism driving the 
effect of cigarette smoking and nicotine on cardiac electrophysiology. Consequently, these 
findings will inform U.S. Food and Drug Administration of tobacco and nicotine-
containing products’ impact on the human cardiac electrical system, and potentially help 
regulate alternative forms of nicotine delivery and protect public health. 
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CHAPTER I  
INTRODUCTION 
Background and context 
Clinical significance of cigarette smoking, nicotine, and cardiac electrophysiology 
Cigarette smoke 
Cigarette smoking is the leading preventable cause of premature death. It is 
responsible for at least 480,000 premature deaths every year in the United States, with more 
than 41,000 of these deaths from exposure to secondhand smoke [1, 2], out of which one-
third are secondary to cardiovascular disease (CVD) [3]. The mortality of current smokers 
among both sexes is three times that of non-smokers [4, 5]. Diseases attributable to 
smoking accounts for about 60% of smokers' deaths and the benefits of quitting smoking 
are dramatic across all age groups, with substantial gains in life expectancy, as compared 
to those who continue to smoke [5]. Furthermore, elevated CVD mortality has been seen 
even among patients smoking fewer than five cigarettes per day, suggesting a nonlinear 
dose-effect relationship [6]. Apart from the 21 common diseases formally attributed to 
cigarette smoking, there are diseases that have not been formally established as being 
caused by smoking (such as infections, hypertensive heart disease, renal failure, intestinal 
ischemia, and other respiratory diseases), and account for a significant excess in mortality 
[4]. The estimated annual smoking-related economic
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burden in the United States is between $289–332.5 billion in direct medical care and other 
economic costs [1, 7]. Smoking alsoappears to have a multiplicative interaction with other 
major CVD risk factors (elevated serum lipid levels, untreated hypertension, and diabetes) 
[2].  In 2016, 15.5% (37.8 million) of U.S. adults were cigarette smokers. The prevalence 
of cigarette smoking was higher among adults who were male, 25–64 years old, of lower 
socio-economic status, of American Indian/Alaska Native descent or multiracial, and 
suffering from psychological distress [8]. 
Nicotine and addiction 
Addiction to the nicotine in tobacco is the proximate cause of these diseases, 
because it sustains smoking behavior by acting on nicotinic cholinergic receptors in the 
brain to trigger the release of dopamine and other neurotransmitters [9]. Release of 
dopamine, glutamate, and gamma-Aminobutyric acid (GABA) [10] is particularly 
important in the development of nicotine dependence, and the extrahypothalamic 
corticotropin-releasing factor may play a key role in withdrawal [11, 12]. Nicotine 
addiction occurs when smokers rely on smoking to modulate mood and arousal, relieve 
withdrawal symptoms, or both. Therefore, the magnitude of public health harm caused by 
tobacco is inextricably linked to its addictive nature [9]. There is a continuum of risk for 
products that deliver nicotine, ranging from the most harmful combusted products (e.g., 
cigarettes) and electronic nicotine delivery systems (ENDS), to medicinal nicotine 
products. 
Although significant research has been conducted to understand the 
pathophysiology of smoking-associated CVD, new research in this era has slowed in recent 
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years. This lag in research is particularly harmful, as tobacco products have continued to 
evolve, and new products, such as ENDS, are a popular source of nicotine, especially 
among children and young adults [13]. In contrast with cigarettes, however, e-cigarettes 
generate an aerosol by heating a liquid, usually consisting of propylene glycol or vegetable 
glycerin, nicotine, and flavoring agents, without any combustion [14]. Despite almost 
complete lack of knowledge regarding the biological effects of these new tobacco products, 
ENDS have been implied to help conventional cigarette smokers quit or curtail smoking. 
ENDS manufacturers are making claims that these products pose fewer health risks and are 
much safer than smoking conventional cigarettes. This postulation is concerning because 
such health claims are likely to lead to increased ENDS use, and may even lead to an 
increase in nicotine dependence in the population at large. Although e-cigarettes deliver 
lower levels of carcinogens than do conventional cigarettes, they still expose users to high 
levels of ultrafine particles and other toxins, such as volatile organic compounds (VOCs) 
[15], that may substantially increase risks for cardiovascular and noncancerous lung 
disease, which account for more than half of all smoking-related deaths, at rates similar to 
conventional cigarettes [16]. 
The primary concern for nicotine in cigarette smoking is an addiction. Tobacco 
combustion products cause most of the adverse health effects from smoking, but some 
health concerns are related to nicotine. Many of these concerns are related to the ability of 
nicotine to release catecholamines, including hemodynamic effects (increase in heart rate, 
transient increases in blood pressure, vasoconstriction of coronary and other vascular beds), 
adverse effects on lipids, and induction of insulin resistance [17]. Both in vitro and in vivo 
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animal studies suggest that nicotine may inhibit apoptosis, enhance angiogenesis, 
exacerbate atherosclerotic disease [18, 19], and produce endothelial dysfunction [20]. 
Cardiac electrophysiology 
Basic cardiac electrophysiology is fundamental in understanding rhythmic cardiac 
function and electrical conduction, as well as changes in electrical activity associated with 
cardiac disease. The primary clinical tool for assessing cardiac electrical events is the 
electrocardiogram (ECG) [21]. The 12-lead ECG remains the most widely available, 
inexpensive, non-invasive, an indispensable tool for the diagnosis and prompt initiation of 
therapy in patients with acute coronary syndromes. It provides the most accurate means of 
diagnosing intraventricular conduction disturbances and arrhythmias, assessing 
cardiovascular risk and screening individuals in high-risk occupations and, in some cases, 
for participation in sports. As a research tool, it is used in long-term population-based 
surveillance studies and experimental trials of drugs with recognized or potential cardiac 
effects [22]. Therefore, ECG is used in clinical trials, as a valid, reliable, repeatable, 
quantitative method that is inexpensive and unbiased by clinical information. 
Most ECGs used clinically are produced from digital signaling and interpreted by 
software using algorithms to assess cardiac rhythmicity, heart rate, heart rate variability 
(HRV), and intervals between conventional ECG landmarks, especially the PR, QRS, and 
QT intervals. These metrics provide essential insight into the autonomic function (HRV), 
atrioventricular conduction (PR interval and segment), ventricular depolarization (QRS), 
and repolarization (QT and JT). There are several major and minor ECG variables 
associated with cardiovascular mortality; namely P wave (duration, interatrial block, and 
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deep terminal negativity of the P wave in V1), QT and Tpeak-Tend (Tp-Te) intervals, QRS 
duration and fragmentation, bundle branch block, ST segment depression and elevation, T 
waves (inverted, T wave axes), spatial angles between QRS and T vectors, premature 
ventricular contractions, and ECG hypertrophy criteria [23-25]. Apart from these 
traditional ECG markers, there is evidence for several other ECG intervals that have also 
been shown to be associated with total all-cause and cardiovascular-related mortality, such 
as PR interval [26-30], JT interval [31, 32] and Tp-Te [33-35]. 
Given its low cost, ubiquity, and safety, ECG is a useful candidate tool for screening 
and risk stratification of asymptomatic participants [36]. Deaths due to smoking-related 
CVD are generally preceded by a subclinical cardiovascular injury that may be detected 
early in the disease process [37]. To improve risk identification and stratification among 
asymptomatic smokers, and to aid in preventative measures, health professionals need 
more sensitive smoking-related markers of early cardiovascular damage. This research 
focus is particularly imperative in the new era of ENDs, as it remains unclear how ENDS 
might compare to cigarette smoke in severity and temporality of associated adverse 
outcomes.  
Implications for public health practice 
Some tobacco control researchers and advocates emphasize the need for strong 
policies that would protect future and current generations from new products that lead to 
nicotine addiction or serve as a gateway to cigarette smoking [16]. Others emphasize the 
different risks for disease associated with different tobacco and nicotine products, and 
argue that policies must prioritize reducing disease risk even if that means allowing for 
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new products that may have high addiction potential [38]. As part of their framework 
announced in 2017, the Food and Drug Administration (FDA)—based on their recognition 
that nicotine makes tobacco products addictive, but that it does not directly cause smokers’ 
cancer, lung disease, or heart disease—has proposed a regulation strategy designed to limit 
nicotine in cigarettes to a minimal or nonaddictive level [39]. The premise is that the mode 
of nicotine delivery, rather than the drug nicotine itself, is the key to reducing harm at a 
population level. This action has the promise of helping current users quit while preventing 
potential future smokers—youths, in particular—from becoming addicted via escalation 
from experimentation to regular smoking [40]. Modeling estimates that, by appropriate 
nicotine regulation, about 5 million adult smokers could quit within a year, and most youths 
and young adults—could avoid becoming regular smokers [41]. Whether this is the right 
approach is unclear, as through it, the FDA Center for Drug Evaluation Research has 
primarily been conducted on targeting smoking cessation rather than dependence on 
nicotine and alternate tobacco products [42]. As smokers find it difficult to achieve desired 
nicotine levels from low-nicotine cigarettes, they may seek to replace cigarettes with other 
tobacco products that deliver nicotine. The FDA expects that making cigarettes minimally 
addictive or nonaddictive would reduce tobacco-related harm by promoting smoking 
cessation or a complete migration to alternative, uncombusted products, and by reducing 
initiation. Although concrete evidence is lacking, there are concerns that ENDs use may 
renormalize smoking behavior, sustain dual-use, and initiate or maintain nicotine addiction 
[13]. ENDS use also could serve as a gateway to the initiation of smoking by ex-smokers. 
Unregulated e-cigarette use also has the potential to erode gains in smoking cessation and 
smoke-free laws [13]. Furthermore, the health effects of nicotine and e-cigarettes have not 
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been well studied, and the potential harm incurred by long-term use of these devices 
remains completely unknown.  
To complement Center for Tobacco Products (CTP) and CTP-funded scientific 
investigations to determine each product’s risks, benefits, and net public health impact, the 
FDA encourages submission of information from additional rigorous research (e.g., outside 
research institutions, or a manufacturer in an application for FDA marketing authorization 
of a new product [40]). Hence, extensive new research is required to assess the health 
effects of nicotine in order to develop appropriate regulatory policies. 
Effects of cardiac autonomic system and cigarette smoke on cardiac action potential 
Direct effects 
Cardiac autonomic nervous system 
Sympathetic and parasympathetic control: Superimposed on the intrinsic cardiac 
control system are the major extrinsic factors—autonomic efferent postganglionic nerve 
terminals— which affect the secretion of hormones into circulation, and the release of 
chemicals directly onto the cardiomyocyte membrane [43]. The autonomic nervous system 
(ANS) plays a vital role in the genesis of several cardiac arrhythmias, both in the atria and 
in the ventricles. Modulation of the autonomic response is a complex process, in which the 
final effect is the product of interactions among central, peripheral, and intracardiac 
components. Autonomic activation alters not only the heart rate, conduction, and 
hemodynamics, but also the cellular and subcellular properties of individual myocytes.  
The cardiac ANS is divided into extrinsic (fibers that mediate connections between 
the heart and the nervous system) and intrinsic (fibers facilitating function within the 
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pericardial sac) components. The extrinsic cardiac ANS is divided into sympathetic and 
parasympathetic components. The fibers of the sympathetic nervous system (SNS) are 
largely derived from major autonomic ganglia along the cervical and thoracic spinal cord. 
The parasympathetic nervous system (PNS) originates predominantly in the nucleus 
ambiguus of the medulla oblongata and is carried almost entirely within the vagus nerve. 
In addition to the extrinsic cardiac ANS, the heart is also innervated by an exquisitely 
complex intrinsic cardiac ANS, with the vast majority of these ganglia organized into 
ganglionated plexi (GP) on the surface of the atria and ventricles, particularly at the sinus 
node, atrioventricular node and pulmonary vein–left atrium junction [43, 44]. There is a 
group of complex extracardiac and intrinsic cardiac neurons that comprise a local 
distributive network, process (both centripetal and centrifugal) information in cardiac 
control, and imply the presence of local information processing [45]. Furthermore, the 
influences of sympathetic and parasympathetic stimulation exert not only different effects 
on atrial and ventricular myocytes, but also during normal and diseased states [44]. 
Generally speaking, increased cardiac sympathetic efferent neuronal tone increases cardiac 
chronotropy, dromotropy, and inotropy; the reverse holds for the effects exerted by 
medullary (parasympathetic) efferent preganglionic neurons [43]. 
Sympathetic nerve stimulation results in well-defined changes in 
electrophysiological properties at the cellular and tissue levels, including enhanced 
conduction in working myocardium and shortening of the action potential duration and 
refractory periods. Sympathetic control of cardiac electrical activity is mediated by the 
activation of β-adrenergic receptors that regulate the activity of select ion channel proteins 
via cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA), or by 
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direct binding of cAMP to channel subunits. The activation of β-receptors regulates the 
function of many ion channels in the heart, including Na+, K+, and Ca2+ channels [46]. 
Sodium and Calcium channels: β-adrenergic receptors’ regulation of cardiac Na+
channels may occur via several distinct mechanisms. PKA-dependent and -independent (a 
more recent and poorer defined pathway) signaling pathways impact cardiac Na+ channel 
function. The indirect pathway engages canonical signaling, including PKA 
phosphorylation of the Na+ channel α-subunit. PKA-independent regulation (direct 
regulation) involves ion channels, such as NaV1.5, CaV1.2, and KV1.5, which are enriched 
in caveolae and colocalized with Cav3. Caveolae are ready reservoirs of select cell 
membrane proteins; β-adrenergic receptor stimulation opens caveolae through a Gαs-
involved, PKA-independent pathway, and increases membrane density of resident ion 
channels [47]. In addition to caveolin-associated augmentation of surface expression and 
channel phosphorylation, sympathetic activation increases L-type Ca2+ channel activity and 
intracellular Ca2+. Phosphorylation of the NaV1.5 channel results in the alteration of the 
voltage-dependent kinetics and whole-cell INa amplitude [48]. There is limited evidence 
for direct regulation of cardiac Na+ currents by parasympathetic activity, but the reversal 
of the effects of β-adrenergic receptor stimulation by acetylcholine has been described [49], 
likely via pre-synaptic inhibition upon muscarinic receptor activation [50]. β-adrenergic 
receptor stimulation appears to alter the voltage-gated calcium current via a dual 
mechanism, perhaps similar to that demonstrated previously for sodium channels [51]. The 
L-type cardiac calcium channel, CaV1.2a, is phosphorylated by PKA, which increases 
open channel probability, and subsequently the overall cellular calcium current [47]. 
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Potassium channels: Sympathetic activation can directly affect all potassium 
currents, including Ito (responsible for transient outward current and level of the plateau in 
action potential). The delayed rectifier K currents IKur, IKr, and IKs are slowly activating 
outward currents that play major roles in the control of repolarization. β-adrenergic 
stimulation regulates IKr through the activation of PKA (an inhibitory effect) and elevation 
of c-AMP (a stimulatory effect through binding to the cyclic nucleotide binding domain of 
the channel), whereas α-adrenergic stimulation is inhibitory. β-adrenergic stimulation also 
accelerates repolarization by augmenting IKs via PKA-dependent phosphorylation of 
Kv7.1 (also termed KvLQT1, encoded by the Kcnq1 gene) [52-54], and β-blockers prolong 
transmural dispersion of repolarization and action potential duration [55]. However, there 
is a potential inhomogeneity of effects of β-adrenergic stimulation on potassium channels 
across different species, which also vary by stimulus and disease states [50]. Vagal 
stimulation produces the opposite effects. Vagal stimulation releases acetylcholine, which 
then activates a potassium current and an inward-rectifying K+ current (IKAch), following 
stimulation of muscarinic (M2) receptors that hyperpolarizes the membrane potential and 
abbreviates the action potential, slowing the Phase 4 depolarization of pacemaker cells [52, 
56]. In contrast, Liang et al. tested acetylcholine shortened action potential duration in ex 
vivo rat ventricular tissue, and the effect was inhibited by a G-protein-coupled inward 
rectifier potassium (GIRK) channel blocker [57]. Furthermore, the muscarinic stimulation 
can also partially reduce the amplitude of the L-type Ca2+ current by inhibiting adenylate 
cyclase. Therefore, vagal stimulation’s effect on cardiac repolarization is complex and may 
differ by species, phenotype, or stimulus.  
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As illustrated in Figure 1.1, sympathetic dominance in humans produces an 
increase in upstroke velocity, amplitude, and conduction velocity, as well as a decrease in 
the effective refractory period. These effects are mainly due to stimulation of β-adrenergic 
receptors and the resulting augmentation of INa, ICa, IKr, and  IKs. Therefore, acute 
sympathetic neural activation results in the shortening of RR interval, P wave, PR interval, 
PR segment, QRS duration, QT, and Tp-Te. 
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Figure 1.1 Effect of Sympathetic nervous activation on human cardiac electrophysiology 
References Effects of SNS activation ECG intervals 
[58] Short P wave / P-P wave 
[59, 60] Short PR interval 
[61] Short PR segment 
[62, 63] Short QRS duration 
[64-66] Short QT interval 
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Nicotine 
Cardiac autonomic nervous system: Nicotinic acetylcholinergic receptors 
(nAchRs) mediate the neural transmission at the ganglia of both branches of the ANS. 
However, different nicotinic receptors at the ganglia play distinct roles in sympathetic and 
parasympathetic cardiovascular responses (Figure 1.2). Specifically, activation of α4β2 
nAchRs elicits a parasympathetic cardiovascular response, and activation of α7 nAchRs 
elicits a sympathetic cardiovascular response [67, 68]. Neff et al. used the perforated patch-
clamp technique in a visualized rat brain stem slice to identify three potential sites of action 
by which nicotine increases the activity of cardiac vagal neurons: (a) direct activation of 
postsynaptic ligand-gated nicotinic channels in cardiac vagal neurons, (b) different 
presynaptic terminals, and (c) postsynaptic glutamatergic terminals [69]. Moreover, in 
various animal models and species, nicotine has been shown to evoke norepinephrine 
release from both the peripheral postganglionic sympathetic nerve endings and adrenal 
medulla [70, 71]. Another potentially sympathoexcitatory mechanism of nicotine involves 
the inhibition of neuronal nitric oxide synthase, which decreases central nitric oxide 
availability, thereby removing its tonic inhibitory effect on central sympathetic outflow 
[72].  
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Figure 1.2 Schematic diagram to illustrate the different direct sites of action for nicotine on the pathways of the cardiovascular 
autonomic nervous system  
SA – Sinoatrial node. AV – Atrioventricular node. 
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Cardiac sodium and calcium channels: The binding of nicotine to the extracellular 
binding site of the nicotinic acetylcholine receptor leads to a conformational change of the 
central pore, which results in the influx of sodium and calcium ions [73, 74]. In addition to 
the increase in intracellular calcium concentration facilitated by sodium influx through the 
nicotine receptor [73], nicotine also evokes calcium influx by direct activation of voltage-
dependent calcium channels [75-77]. More specifically, the L-type Ca2+ channels—Cav 
1.2 channel, in particular—have been implicated in nicotine addiction, and are controlled 
by the SNS and stimulated by nicotine [78, 79]. Therefore, several studies have consistently 
shown that nicotine can both indirectly (catecholamine-mediated) and directly activate 
voltage-gated sodium and calcium ion channels, depolarize membrane potential, and 
increase cardiac contractility [80-83].  
Cardiac potassium channels: On the other hand, nicotine directly blocks multiple 
types of potassium currents, (A-type K+ currents (Ito current/Kv4.3 channel), delayed 
rectifier K+ currents (IKr/HERG) and inward rectifier K+ currents (Ik1/Kir2.1), 
independent of nicotinic receptor stimulation or catecholamine release [84-86]. However, 
the ex vivo studies on the effects of nicotine on the duration of action potential have been 
inconsistent. Some found that nicotine shortens the action potential duration (particularly 
phase 2) [83], whereas others found that nicotine prolongs it [87]. These discrepancies 
could be related to the time from drug administration [82], drug concentration [80, 88] or 
the concomitant increase in force [89]. The shorter phase 2 could also reflect nicotine 
stimulation of L-type Ca2+ channel, which, together with potassium channels, dictate the 
duration of this phase of the action potential. Similar dose-dependent effects of nicotine 
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are seen in the sinoatrial node, where low doses of nicotine reduce [81, 88]—and large 
doses increase [88]—the spontaneous cycle length of sinoatrial node pacemaker cells. 
At physiological doses, nicotine can indirectly (through the sympathetic nervous 
system) and directly (via immediate effects on cardiac ion channels) stimulate sodium and 
calcium channels and block potassium channels. Per the pathways mentioned above, 
nicotine is expected to induce multiple alterations in the surface ECG, including shortening 
of the P wave, PR interval, PR segment, and QRS duration, and prolongation of QT 
corrected (QTc) and Tp-Te. However, very few researchers have attempted to explore the 
effects of nicotine on all ECG intervals in humans.  
Cigarette smoking and its non-nicotine constituents 
Cardiac autonomic nervous system: Cigarette smoke-induced cardiovascular 
effects are at least partly due to stimulation of sympathetic neurotransmission, and can 
theoretically manifest at four different sites of the sympathetic nervous system: the brain, 
pre-ganglionic and post-ganglionic sympathetic nerves, and the adrenal medulla [71]. 
Acute cigarette smoking increases efferent sympathetic nerve activity, primarily via the 
release of the catecholamines norepinephrine, and epinephrine (Table 1.1). This 
catecholamine release increases myocardial work and oxygen consumption through an 
increase in blood pressure, heart rate, and myocardial contractility [19]. However, several 
studies suggest that the primary effect is from direct pharmacologic stimulation of nicotinic 
acetylcholine receptors, as well as the catecholamine release from localized peripheral 
postganglionic sympathetic nerve endings and the adrenal medulla [90, 91]. Despite 
evidence that sympathetic tone is increased during smoking, either by increased release or 
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decreased clearance of catecholamines at neuroeffector junctions via inhibition of 
monoamine oxidase (MOA) [92], Grassi et al. revealed that the central sympathetic activity 
is inhibited, presumably via counteracting baroreceptor reflexes [90].  
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Table 1.1 Summarizes the key studies on the acute effect of smoking on the circulating catecholamines. E – Epinephrine, NE – 
Norepinephrine. Dopa - Dopamine 
Author 
Date 
Journal 
Participants Cigarette Plasma/ urine Sampling frequency Catecholamines Result 
Comment 
/Nicotine 
Cryer 
1976 
NEJM 
10 healthy men 
(24-42 y) 
Two standard non-
filtered cigarettes in 
10 minutes 
Plasma 
-10, 0, 2.5, 5.0, 7.5, 
10, 12.5, 15.0, 17.5, 
20, 25, 30 (mins) 
E, NE 
Max at 10 and 
12.5 min for E 
and NE 
E significantly 
higher even at 
end. 
Siess 
Circulation 
1982 
6 healthy men, 
mean age 30 y 
Two cigarettes of
1.6 mg nicotine each Plasma End of smoking E, NE 
Increased from 
baseline 
Mundal 
1988 
Am J 
Hypertens 
18 normotensive, 
13 hypertensive 
white men (mean 
age 42 y) 
Two cigarettes, 1.7 
mg nicotine Plasma 
Baseline, after each 
cigarette and after 
60 minutes from 
start of smoking 
E, NE 
E increased after 
second cigarette 
(not after 60 min) 
only among 
hypertensive 
group 
15 ng/ml after 
1st cigarette 
and 23 ng/ml 
after second 
cigarette 
Niedermaier 
1993 
Circulation 
8 healthy, 5 men 
(19 – 44 y) 
Low and medium-
nicotine research 
cigarette (30-45 
mins apart) 
Plasma 
10 mins after each 
smoking period (to 
coincide with max 
catecholamines) 
E, NE No difference 
7 and 16 
ng/ml after 
low and 
medium 
cigarette 
Grassi 
1994 
Circulation 
8 men, 1 woman, 
(21 – 48 y) 
One filtered 
cigarette 1.1 mg 
nicotine (within 5 
mins) 
Plasma End of smoking E, NE Significant increase 
After 1st 
cigarette 44 
ng/ml 
Krzysztof 
1998 
Circulation 
14 healthy 
smokers (13 
men). Mean age 
23 y 
Two cigarettes 
containing 1.1 mg 
nicotine (5 mins 
apart). 45 mins later 
smoked third 
cigarette 
Plasma 
Outset of study and 
3 mins after second 
and third cigarette 
NE 
Increased from 
171 (baseline) to 
189 (after 2 
cigarettes) and 
214* (3rd 
cigarette) 
17 ng/ml and 
20 ng/ml of 
nicotine, after 
2nd and 3rd cig. 
Smoked third  
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Gourlay 
1997 
Clin 
Pharmacol 
Ther 
12 healthy male 
smokers, mean 
age 38 y 
6 got nicotine nasal 
spray (1 x 0.5 mg in 
each nostril) and 
other 6 did smoking 
(usual brand) 
Plasma 
0, 2, 4, 6, 8, 10, 15, 
20, 25, 30, 45, and 
60 mins 
E, NE 
Venous E and NE 
remain 
unchanged 
Bragg 
1956 
J Appl Physi 
11 healthy young 
men 
Their choice of 
standard cigarettes 
during 2 / 8 hour (4 
and 10 cigs) 
Urine 8-hour urine collection E, NE 
E increased, NE 
unchanged 
Benowitz 
1993 
JACC 
12 healthy male 
smokers, 31 – 65 
y 
cigarette smoking 
(own choice), 
transdermal nicotine 
(21 mg/d) and 
placebo 
Urine 24 hr Urine collected day 5 Dopa, E, NE 
Significantly 
higher with 
smoking 
Benowitz 
1989 
Ann Intern 
Med 
8 healthy male 
smokers 
oral snuff, chewing 
tobacco, and 
cigarettes  
Urine 24-hour urine after 3- or 4-day blocks Dopa, E, NE 
Significantly 
higher with 
smoking 
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Non-nicotine constituents: 
In addition to nicotine, several other cigarette components have been implicated in 
inducing proarrhythmia, such as VOCs (aldehydes [acrolein, formaldehyde, acetaldehyde, 
crotonaldehyde], benzene, toluene), particulate matter, gases (carbon monoxide), and 
polycyclic aromatic hydrocarbons. It is estimated that about 90% of non-cancer mortality 
from tobacco smoke is due to aldehydes (acrolein, formaldehyde, and acetaldehyde) [93]. 
In animal models, a single exposure to acrolein significantly increased HRV and 
arrhythmia independent of heart rate, possibly through activation of the transient-receptor 
potential ankyrin-1 channel (TRPA1), an irritant receptor channel found in the airways [94, 
95]. Treatment with atenolol reduced this response, whereas atropine enhanced it, 
suggesting parasympathetic dominance and sympathetic modulation [95]. Non-nicotinic 
alkaloids, such as nornicotine or anabasine (which represent 8–12% of total alkaloid 
content in tobacco), also exert an agonistic activity on nicotinic receptors [96]. Acute 
exposure to toluene, the most abundant aromatic compound in mainstream smoke from 
full-flavored cigarettes, enhances heart rate and blood pressure at baseline conditions, 
primarily due to systemic increases in circulating catecholamines [97, 98], and the 
enhanced protein expression of β1 adrenergic receptors [97]. Additionally, intravenous 
acetylaldehyde in anesthetized cats has been found to increase systemic blood pressure and 
heart rate (presumably from release of endogenous catecholamines from cardiac tissue) 
[99]. Formaldehyde has been shown to induce significant bradycardia and negative 
inotropic responses in both in situ preparations of guinea pig and rabbit hearts, and in vitro 
cardiac preparations [100]. Notably, the negative chronotropic effect of formaldehyde in 
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animals seems to be caused mainly by the inhibition of sympathetic nervous activity 
through the central nervous system [100]. 
Several non-nicotine cigarette ingredients have long been recognized as cardio-
toxic and linked with cardiac electrical activity disturbance and arrhythmias, such as 
aromatic compounds [101], carbon monoxide [102], and aldehydes [99]. However, 
literature on their individual drug concentration effects on cardiac ion channels and the 
action potential is scarce.  
Cardiac sodium and calcium channels: Toluene inhibits activated currents through 
ligand and voltage-gated sodium and calcium channels [97, 103-106]. Phenol has been 
shown to exert a dose-dependent negative inotropic effect in an isolated mammalian 
cardiac muscle, possibly via blocking calcium channels [107]. In a patch-clamp 
electrophysiology and confocal imaging experiment with isolated ventricular myocytes, 
carbon monoxide activated nitric oxide synthase. This led to the nitric-oxide-mediated 
nitrosylation of Nav1.5, as well as increased the sustained (late) component of the inward 
Na(+) current, and inhibited peak Nav1.5 current amplitude, ultimately resulting in 
prolonged action potential and associated intracellular Ca(2+) transient [102]. In addition, 
carbon monoxide inhibits native rat cardiomyocyte L-type Ca2+ currents and the 
recombinant α1C subunit of the human cardiac L-type Ca2+ channel [108, 109]. 
Formaldehyde and other aldehydes have previously been shown to cause dramatic 
deceleration of sodium inactivation, depress Ina, and prolong action potential [110-113]. 
On the other hand, acetaldehyde has also been shown to increase the ICa, and thereby 
increase the contractile force [114], Its effects can be potentiated by the additional 
stimulation of α-adrenergic receptors [115]. Several other cigarette constituents have also 
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been found to, at minute quantities, significantly inhibit sodium and calcium channels in 
isolated cardiac cells, such as cyanide [116, 117], lead [118], and cadmium [119]. 
Particulate matter, encountered during cigarette smoking, is also a significant cause of 
cardiovascular morbidity and mortality. Particulate matter has been shown to dysregulate 
prominent Na+ and K+ channel pathway genes [120], and carotid body sensitivity [120].  
Cardiac potassium channels: Aldehydes have been proven to considerably inhibit 
IK1 and Ito in animal atrial and ventricular myocytes [121-123]. In one study, ethanol and 
acetaldehyde inhibited the (Na+ + K+)-activated ATPase activity of plasma membranes 
prepared from a guinea-pig heart in a dose-dependent manner [124]. In addition, several 
volatile agents found in cigarette smoke, commonly used as anesthetics, have been shown 
to inhibit G-protein-coupled inwardly rectifying potassium channels [125]. Benzene 
derivatives inhibit delayed rectifier K+ currents [126], specifically IKr2.1, in a voltage-
independent manner [127]. Carbon monoxide also inhibits inward-rectifying potassium 
(Kir) channels, and prolongs the action potential duration [128, 129]. In their study, Ficker 
et al. demonstrated that, despite there being an increase in cardiac calcium current, there is 
reduced trafficking of cardiac potassium channel (hERG channels) to the cell surface 
among patients treated with arsenic trioxide, resulting in QT prolongation [130]. Another 
study revealed that arsenic trioxide blocks both IKr and IKs at clinically relevant 
concentrations. However, it also activates IK-ATP [131]. Graff et al. discovered that 
exposing rat cardiac myocytes to noncytotoxic concentrations of zinc and vanadium slowed 
the spontaneous beating rate [132]. 
In summary, the studies on the several components of cigarette smoke with known 
or suspected cardiotoxicity consistently show that they depress sodium and potassium 
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channels, with some mixed effects on calcium channels, and a range of effects on ECG 
(Figure 1.3). Overall, the constituents appear to result in prolonged action potential 
duration from inhibition of sodium and potassium channels. Apart from formaldehyde, 
most other cigarette non-nicotine constituents have been shown to stimulate the cardiac 
sympathetic nervous system. With >4000 non-nicotine chemicals in cigarette smoke, and 
a complex mixture of effects on the sympathetic and parasympathetic pathways, the non-
nicotine constituents can have a varied effect on surface ECG. Furthermore, most of the 
studies on the effects of non-nicotine constituents of cigarette smoke are derived from ex 
vivo or in vitro animal studies, with concentrations typically higher than those possibly 
encountered during cigarette and nicotine use. For instance, carbon monoxide causes tissue 
hypoxia, and, in addition to nicotine, has been implicated in promoting cardiac arrhythmias 
[133]; however, Benowitz et al. found that when carbon monoxide was administered under 
conditions similar to those of cigarette smoking, it had no significant effect on blood 
pressure, heart rate, plasma catecholamines, platelet aggregation, or C-reactive protein 
[134]. These results suggest that the short-term chronotropic, pro-thrombotic, and pro-
inflammatory effects of smoking are probably due to components of cigarette smoke other 
than carbon monoxide. 
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Figure 1.3 Direct effects of nicotine and non-nicotine constituents on cardiac ion channels and action potential. SNS – Sympathetic 
Nervous Activation 
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Indirect (systemic) effects 
There are several short- and long-term homeostatic mechanisms to ensure adequate 
blood flow, pressure, distribution, and perfusion, and are categorized into three groups: 
neural, humoral, and autoregulatory mechanisms. These mechanisms can also indirectly 
alter cardiac autonomic output and electrophysiology. Table 1.2 summarizes the stimuli, 
receptors, and physiologic effects most pertinent to cigarette smoking and nicotine-related 
changes in human autonomic reflexes. 
Neural reflexes to tobacco exposure: The baroreflex feedback loop is one of the 
most important mechanisms controlling arterial pressure on a beat-to-beat basis. It achieves 
this through arterial baroreceptors located in the carotid sinus and aortic arch. These 
receptors are mechano-sensitive, and the distension of the vessels that occurs at each heart 
beat leads to action potential generation on peripheral nerves that transmit to the central 
nervous system, buffering arterial pressure fluctuations through changes in sympathetic 
and parasympathetic activity. Therefore, when blood pressure rises, the baroreceptor 
afferent tone increases, leading to increased vagal efferent activity and diminished 
sympathetic outflow. These effects will lead to a decrease in cardiac output by decreasing 
heart rate and cardiac contractility.  Additionally, the fall in sympathetic tone to blood 
vessels, as well as increased vagal effect activity (through increased guanylyl cyclase and 
cGMP activity) leads to vasodilation and diminished vascular resistance. There is strong 
evidence that this crucial inhibitory role of the baroreflex arc is blunted in habitual smokers, 
and also impaired during acute exposure to smoking [72, 135, 136]. Grassi et al.’s study 
showed that there is sympathetic activation induced by smoking via increased release or a 
reduced clearance of catecholamines at the neuroeffector junctions. However, the central 
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sympathetic activity is inhibited by smoking, presumably via baroreceptor stimulation 
triggered by a pressor response to smoking [90]. There is also evidence that nicotine 
possibly decreases the baroreceptor sensitivity [137]. Besides nicotine, there are several 
other cigarette components, mainly PM 2.5, that directly alter baroreflex responsiveness in 
smokers [72, 138]. In one study, a one-time exposure to acrolein caused a decrease in the 
sensitivity of baroreflex and increased incidence of arrhythmia in rats [139].  
The peripheral arterial chemoreceptors in the carotid and aortic bodies are 
stimulated by decreased arterial PO2, increased PCO2, and increased H+ concentration. 
Their stimulation causes hyperventilation, as well as increases in sympathetic neural 
activity and the rate and volume of breathing; chronic arterial chemoreflex sensitization in 
smokers could also lead to sustained sympathetic activation. Arterial chemoreceptors are 
activated by hypoxia, and chronic smokers may be at risk to toxic effects of carbon 
monoxide in tobacco smoke. Perez et al. showed that acrolein-exposure-induced 
cardiovascular effects in rats (i.e., an increase in systolic, diastolic and mean arterial blood 
pressure during exposure, and a decrease in cardiac contractility one day after exposure) 
were prevented after a blockade of carotid body signal transduction. This suggests that 
acrolein-induced cardiovascular responses may be mediated by carotid body-triggered 
changes in autonomic tone [140]. However, to date, there is no evidence for augmented 
arterial chemoreceptor sensitivity in habitual smokers. Instead, nicotine does not affect 
chemoreflex sensitivity, as evidenced by unchanged minute ventilation, apnea duration, 
and oxygen saturation after nicotine and placebo in normoxia [141, 142].  
Airways are lined with vagal afferent nerve fibers, including non-myelinated 
afferent C-fibers sensitive to noxious chemicals. A subset of these vagal C-fibers expresses 
27 
the TRP channels, which sense a variety of mechanical and chemical stimuli, such as 
mechanical stretch, sheer stress, oxidative stress, inflammation, and endogenous and 
exogenous chemicals. When exposed to irritants, TRP channels induce the local release of 
neuropeptides from cells, resulting in a local inflammatory response that reflexively 
increases efferent sympathetic nerve activity. This may cause further airway irritation and 
reflex responses, such as cough and reactive airway dysfunction [50, 143, 144]. However, 
there is little evidence to support whether smoking and its constituents directly activate 
TRP channels to modulate the human cardiac autonomic nervous system. 
There are also respiratory-related changes in heart rate, specifically termed 
respiratory sinus arrhythmia, to help match pulmonary blood flow to lung inflation, and to 
maintain an appropriate diffusion gradient for oxygen in the lungs (heart rate increases 
during inspiration and decreases during the post-inspiration/expiration period) [145]. 
Consequently, different respiratory patterns during or after cigarette smoking may 
differentially affect cardiac autonomic function [146]. Cardiopulmonary receptors are 
found in low-pressure portions of the circulation, such as walls of the atria and pulmonary 
arteries. These mechano-sensitive receptors are activated by the distension of the vessel 
walls, responding to changes in central blood volume. The cardiopulmonary baroreflexes 
normally exert a tonic inhibitory influence on the SNS. However, cigarette smoking and 
nicotine product use in humans does not typically produce challenges that are extreme 
enough to affect these cardiopulmonary receptors or other similar innate reflexes that also 
alter cardiac electrophysiology (such as temperature, hypoxia, acidosis etc). 
Autoregulation: Local, self-regulatory mechanisms, including chemical and 
myogenic controls, allow each region of tissue to adjust its blood flow, and thus its 
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perfusion. Chemosensitive nerve endings are also found throughout the cardiovascular and 
respiratory systems, and are stimulated by several exogenous chemicals and endogenous 
chemicals formed and released in response to conditions such as hypoxia, ischemia, certain 
mechanical demands, inflammation, or toxin exposures. The efferent pathways of the 
reflex involve inhibition of sympathetic outflow to peripheral vessels and increased activity 
in efferent vagal fibers to the heart [50]. The myogenic response is a reflex to the stretching 
of the smooth muscle of the arteriolar walls as changes in blood flow occur through the 
vessel (e.g., vasoconstriction in response to increased intraluminal pressure). Increased 
peripheral vascular resistance, cigarette smoking, and nicotine also have detrimental effects 
on coronary microvascular function (e.g., increases in coronary flow velocity and 
resistance, and decreases in flow reserve) and can cause vascular dysfunction [147-151], 
possibly via β-adrenergic receptor [152].  
Humoral to tobacco exposure: Several studies have suggested that humoral systems 
play a vital role in maintaining cardiac electric activity, and changes in their production or 
action pathways may contribute to various cardiac diseases. Beyond the neurotransmitters 
acetylcholine and norepinephrine, there is a local presence of peptidergic and nitrergic 
neurons along with their associated neurotransmitters, such as neuropeptide-Y, vasostatin, 
galactin, vasoactive intestinal peptide, nitric oxide synthase, and angiotensin-II [153, 154]. 
Neuropeptide-Y, coreleased by prolonged sympathetic activation, reduces acetylcholine 
release from the nearby vagal nerve ending, and it is an excellent example of 
sympathovagal cross-talk. These non-cholinergic, non-adrenergic neurotransmitters often 
exert effects similar to cholinergic or adrenergic agonists or antagonists [153]. The release 
of these neurotransmitters/modulators is often highly dependent on the level of neuronal 
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stimulation, and they tend to be slowly diffusing molecules that often function as 
neuromodulators, rather than classical neurotransmitters. 
Smoking has multiple effects on hormone secretion, some of which bear crucial 
clinical implications, and are mainly mediated by nicotine. Most acute data are from 
nicotine administration, whereas chronic data are predominantly from studies on cigarette 
smokers. Smoking affects pituitary, thyroid, adrenal, testicular and ovarian function, 
calcium metabolism, and the action of insulin differently in acute and chronic conditions 
[155, 156].  In particular, the activation of nicotinic acetylcholine receptors in the adrenal 
medulla leads to increased circulating catecholamine levels with corresponding 
cardiovascular and metabolic responses. The renin-angiotensin-aldosterone system 
(RAAS) and adrenal gland is also activated by the hypothalamic-pituitary-adrenal axis 
[155, 156].  
Other mechanisms by which smoking, and nicotine can influence cardiac 
autonomic function are inflammation and oxidative stress. The role of autonomic function 
in regulating oxidative stress is supported by previous evidence that the increase in 
adrenergic drive may result in catecholamine excitotoxicity, increased oxidative stress, and 
free-radical myocardium injury. There are two main phases in cigarette smoke; particulate 
phase and gas phase [157]. The two phases are rich in free radicals, and non-radical 
oxidants. Therefore, acute and chronic exposure to smoking causes increased oxidative 
stress from direct damage by radical species and the inflammatory response, as well as 
through sympathetic neural activation [72, 158-160]. In one study, smoking decreased the 
overall α- and β-adrenergic receptor concentration almost immediately after tobacco smoke 
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exposure in rats—perhaps through receptor desensitization resulting from a release of 
catecholamines—but was rapidly reversible after the termination of the exposure [161].  
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Table 1.2 Potential mechanisms of indirect effects of cigarette smoking on human cardiac electrophysiology 
System Receptors Stimulus Effect on SNS 
Effect on 
PNS Studies on the effects of smoking / nicotine 
Baroreflex Carotid artery / 
Aorta  
High Blood 
Pressure 
Decrease Increase Activates the system by increasing blood 
pressure through release of catecholamines 
from end terminals. Smoking also impairs 
the baroreflex system 
Chemoreflex Carotid / aortic 
(peripheral), 
medulla (central) 
Low PaO2, High 
PaCO2/pH 
Increase 
(increase 
pulmonary 
ventilation) 
- Nicotine does not increase chemoreflex 
sensitivity to hypoxia. 
Temperature CNS High Temp Increases - Temperature increases in lungs; decreases in 
skin temp 
Inflammation / 
Oxidative stress 
Lung afferent C 
fibers, vascular, 
myocardial 
Direct / Reactive 
Oxygen Species 
Increase Decrease  Increases inflammation and oxidative stress 
during acute and chronic exposure 
Endocrine hypothalamic–
pituitary axis 
Increase - Chronic: increases thyroid hormones, 
cortisol, possibly testosterone and estradiol. 
Decreases prolactin and growth hormone 
Acute: Increases prolactin, cortisol, growth 
hormone, vasopressin, endorphin, 
neuropeptide Y 
Cardiopulmonary  Ventricles High SNS (low 
vol LV) 
Decrease Increase - 
Pulmonary Pulmonary chemical stimuli, 
inflammation 
? Increase - 
Bainbridge Atria High blood vol Increase Decrease - 
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Literature review of effects of autonomic nervous system 
and smoking on electrocardiogram 
Autonomic nervous system 
Heart rate: The sinoatrial node, also referred to as the pacemaker of the heart, 
coordinates heart contractions. Located in the upper right atria wall, it generates impulses 
that result in cardiac contraction and determines the heart rate. The ANS predominantly 
determines the actual heart rate, but nonautonomic contributions (e.g., hypoxia and 
temperature via chemoreflex and baroreceptors pathways) also affect the intrinsic heart 
rate. The heart rate provides a static index of the net effects of autonomic input to the sinus 
node, but it does not reflect direct information about individual sympathetic or 
parasympathetic input. However, this simple measure has prognostic value, as reflected in 
population-based studies, in which high resting heart rate (net predominance of 
sympathetic influence) is associated with increased all-cause mortality, death from CVD, 
and sudden death [162-164]. The elevated heart rate may not only predict the outcome, but 
may also be an actual causal determinant of CVD through several different mechanisms 
[165].  
Heart rate variability: Efferent sympathetic and vagal activities directed to the sinus 
node are characterized by a synchronous discharge with each cardiac cycle that can be 
modulated by central (vasomotor and respiratory centers) and peripheral (oscillation in 
arterial pressure and respiratory movements) oscillators. These oscillators generate 
rhythmic fluctuations in efferent neural discharge that manifest as short- and long-term 
oscillation in the heart period. Analysis of these rhythms may permit inferences on the state 
and function of (a) the central oscillators, (b) the sympathetic and vagal efferent activity, 
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(c) humoral factors, and (d) the sinus node [166]. The oscillation in the intervals between 
consecutive heartbeats can be measured for indices of HRV, using either time domain 
approaches (based on statistical analysis of R-R intervals) or frequency domain approaches 
(spectral analysis of a sequence of R-R intervals) [166]. Large population studies have 
shown a higher risk of coronary artery disease, death, and cardiac mortality in individuals 
with decreased HRV (in both healthy populations and patients with cardiac disease) [167]. 
P wave: The P wave is the expression of atrial depolarization and intraatrial 
conduction. Electrocardiographic P wave indices consist of the P wave duration, 
morphology, and amplitude, and provide information about the atrial structure and 
function. A prolonged P-wave duration (>120 ms) is considered a marker of atrial 
cardiopathy, which, in chronic cardiac disease, is usually reflective if reduced atrial 
conduction related to architectural changes of atrial walls. P-wave duration is affected by 
autonomic tone. In general, both sympathetic stimulation and parasympathetic blockade 
shorten P-wave duration, whereas sympathetic blockade prolongs it [58]. P-wave terminal 
force in lead V1 (PTFV1) is defined as the value of the amplitude multiplied by the duration 
of the terminal’s negative deflection of the P wave in lead V1 of a standard 12-lead ECG. 
P-wave area (PWA) is the total geometric area under the P wave in the 12-lead ECG. It is 
usually represented by the product of the duration and peak amplitude of the P wave, and 
is measured in microvolt × milliseconds. Both of these P-wave indices, together with P-
wave axis (net direction of electrical forces within the atria), are also markers of atrial 
cardiopathy [168, 169]. Therefore, acute sympathetic activation may shorten P-wave 
duration, whereas chronic sympathetic activation may prolong P-wave duration from long-
term structural atrial remodeling. The P amplitude, which is mostly governed by atrial 
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pressures, may be increased in height (and in depth of PTFV1) in acute and chronic 
sympathetic stimulation.  
PR interval: PR interval is the period of time from the start of the P wave (atrial 
depolarization) until the start of the QRS complex (ventricular depolarization). Therefore, 
the determinants of PR interval are atrial depolarization and the conduction time from the 
sinus node to the atrioventricular node, His bundle, and Purkinje fibers [170].  The duration 
of PR interval is normally between 120 and 200 ms. In most cases, a prolonged PR interval 
(>200 ms) is determined by conduction delay in the atrioventricular node. The ANS’s acute 
effects on PR intervals are well known, considering that autonomic innervation influences 
the conduction through the atrioventricular node junction by modulating the refractory 
period [61, 171]. However, in the chronic state, autonomic-imbalance-induced atrial 
fibrosis may also cause PR interval prolongation by slowing atrial depolarization and 
dromotropy. Both short [26, 27, 29, 30] and prolonged [30, 172-174] PR intervals have 
been associated with adverse clinical outcomes (stroke, atrial fibrillation, and all-cause 
mortality). 
QRS complex: The QRS complex represents the electrical impulse as it spreads 
through the ventricles, and depicts ventricular depolarization. Ventricular depolarization is 
also influenced by autonomic modulation of the heart. In humans, increased sympathetic 
tone by β-adrenergic stimulation shortens overall QRS duration [175], heterogeneity of 
ventricular activation during disease states, and bundle branch blocks (mechanical and 
electrical dyssynchrony) [176]. The QRS complex voltage reflects the viable left 
ventricular mass and can be increased (e.g., athlete’s heart, hypertensive heart disease 
[177]) or decreased (post-myocardial infarction, infiltrative cardiomyopathies, etc. [178]) 
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during different disease states by several mechanisms [179], and both carry critical clinical 
implications [180-182]. The QRS amplitudes can also potentially be affected by the cardiac 
ANS [183-185]. However, stimulation of the left stellate ganglion produces little or no 
change in conduction velocity in the Purkinje  system, or in the pattern of epicardial 
depolarization, suggesting that cardiac sympathetic nerve stimulation does not result in  
significant changes in the sequence of ventricular excitation [61]. 
QT interval: The QT interval is a marker of ventricular depolarization (QRS 
duration) and repolarization (JT interval), and autonomic tone is the primary determinant 
of their duration [65, 186]. Changes in autonomic tone may alter QT intervals both 
indirectly, by modulating basal heart rate, and directly, by affecting ventricular 
repolarization kinetics of myocardial cells through neural and receptor-mediated 
mechanisms [53, 54, 57]. The effect of sympathetic nervous activity on the QT has been 
demonstrated [187-190]; however, in their study, Cappato et al. did not find that 
sympathetic tone influenced QT significantly, but rather that the cholinergic system 
appeared to slow down ventricular refractoriness and QT interval [191]. 
T wave: The T wave is the asymmetrical wave in the ECG that reflects ventricular 
repolarization; it comes after the QRS complex and typically lasts approximately 150 ms. 
The difference between the peak of the T wave and the isoelectric level during the same 
heart cycle is defined as T-wave amplitude (TWA). Several studies have suggested that 
TWA decreases, and even may invert, with sympathetic stimulation; conversely, the 
additional role of the cholinergic system remains unclear [192]. The Tp-Te interval is an 
index of transmural dispersion of repolarization, a marker of ventricular arrhythmia 
vulnerability [193]. An increase in Tp–Te reflects increased sympathetic nerve activity 
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[194], rather than the release of circulating norepinephrine [194]. However, more recently, 
the influence of the ANS on the TWA and Tp-Te interval has fallen under heavy scrutiny, 
and appears to be an unreliable index of myocardial sympathetic activity [195-197]. 
In summary, acute and chronic cardiac autonomic imbalance varies by phenotype 
(normal and diseased states), and influences several ECG parameters differently. 
Role of β-adrenergic receptors 
Physiologic doses of epinephrine alter electrophysiology through β-receptor 
activation, and manifest as an acceleration of atrioventricular nodal conduction and 
shortening of refractoriness in the atrium and ventricle [198]. In contrast, norepinephrine 
slows atrioventricular nodal conduction and lengthens the atrial and ventricular effective 
refractory periods [199]. Therefore, norepinephrine may counteract several of the 
electrophysiological effects of circulating epinephrine during physiologic degrees of stress. 
Furthermore, a-adrenergic stimulation by epinephrine in the presence of propranolol was 
found to prolong atrial and ventricular refractoriness [199].  
Most studies on the effect of β-adrenergic receptors on cardiac electrophysiology 
have been performed with either propranolol, a non-selective β-blocker, or isoproterenol, 
a non-selective β-adrenoreceptor agonist. Propranolol decreases heart rate and prolongs 
atrioventricular nodal conduction [200], and has been shown to have no significant effect 
on intra-ventricular conduction. Shortening of action potential plateau was also not evident 
after treatment with propranolol in normal cat ventricular muscles [89]. In the sinoatrial 
node and left atrial appendage cells of the guinea-pig heart, propranolol antagonized the 
positive chronotropism of nicotine and norepinephrine [88]. Studies conducted on five 
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human volunteers showed that intravenous propranolol followed by smoking significantly 
decreased cardiac output, and significantly increased blood pressure and systemic vascular 
resistance compared to smoking alone [201]. Similar effects were observed in another 
study among 10 participants [202]. Smoking alone increased cardiac output, mean arterial 
blood pressure, and decreased the calculated systemic vascular resistance [201]. The 
cardiac output increases were due to a fall in systemic vascular resistance. The effect is 
exaggerated after propranolol, potentially via the inhibition of β-adrenergic receptors, 
either by preventing the vasodilatory effect of β-2 adrenergic stimulation, or as increased 
availability of α-receptors may result in unopposed pronounced effects of vasoconstriction 
from epinephrine. However, another study was conducted using 80 mg of oral propranolol 
on six volunteers, and there was no significant difference from the placebo in blood 
pressure or forearm hemodynamics, and no prevention of the acute vascular effects of 
cigarette smoking with β-blocker pre-treatment [203]. β-blockers are first line therapy for 
patients with Long QT syndrome (LQTS)—a genetic disorder that can potentially cause 
life-threatening cardiac arrhythmia, is characterized by delayed myocardial repolarization, 
and manifests as QT prolongation [204]. The response to β-blockers and epinephrine 
depends on the genotype [204, 205]. Therefore, the differences in β-adrenergic receptor-
mediated effects on ventricular repolarization are likely related to the stimulus (e.g., 
frequency of cigarette smoking), dose (route) of propranolol use, and the underlying 
genotype. Furthermore, the plasma propranolol steady-state concentration is lower among 
smokers compared to non-smokers, possibly via an increased rate of drug metabolism 
[206].  
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Besides β-adrenergic receptors and muscarinic receptors from the cholinergic 
system, there are several other receptors (α-adrenergic receptors, dopamine receptors, and 
adenosine receptors) found throughout the myocardium, with critical clinical effects on 
ECG (Table 1.3). However, the impacts of smoking and nicotine on the ECG via receptors 
other than β-adrenergic receptors are not well defined.  
Table 1.3 Effects of cardiac receptors on chronotropy, dromotropy and inotropy 
Neurotransmitter Receptors Chronotropy (SA node) 
Dromotropy 
(AV node) 
Inotropy 
(Ventricle) 
Norepinephrine 
α1 + + + 
β1 + + + 
β2 + + + 
Dopamine D1, D2, D3, D5 + + ? 
Acetylcholine M2 - - - 
Acute and chronic exposure from smoking 
Chronic exposure to cigarette smoke (nicotine and non-nicotine constituents) 
Due to the injurious and addictive nature of smoking, it is not ethical to perform an 
experimental study to investigate the chronic effects of smoking and nicotine-containing 
products in humans. Therefore, studies can best describe associations of outcomes 
(biomarkers of CVD and risk) from occupational exposures or chronic smoking. 
Occupational exposure to polycyclic aromatic hydrocarbons results in decreased HRV 
[207]. A similar decrease in parasympathetic activity has been observed in workers 
exposed to organic solvents (n-hexane, xylene, and toluene) [208]. Sub-chronic and long-
term exposure to ambient fine particulate matter (PM2.5) at concentrations several orders 
of magnitude lower than those in cigarette smoke has been associated with increased QTc 
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duration in an elderly cohort [209]. Among 34 middle-aged individuals with metabolic 
syndrome, QRS and QTc intervals increased and HRV decreased 2 h after exposure to 
concentrated ambient ultrafine particles [210].  
Table 1.4 A (atrial electrocardiographic indices) and B (ventricular 
electrocardiographic indices) summarizes the major human studies on the chronic effects 
of smoking. Overall, most large studies (sample size of greater than 100 smokers) 
consistently show that PR interval is decreased among chronic smokers compared to non-
smokers. We were not able to find any study that directly investigated the effect of smoking 
on the PR segment. In a prospective study of 60 smokers, Varenicline (partial agonist at 
the α4β2 nicotinic acetylcholine receptor) treatment was associated with a near-significant 
attenuation in PR interval (varenicline: 163.5±18.3 ms, vs. placebo: 168.2±17.9 ms; P 
=.053). However, RR interval, QT interval, and QTd were not significantly altered [211]. 
Two studies showed shorter P duration but increased P amplitude among smokers [212, 
213]. The effects of smoking on QRS duration were the most varied.  Most studies 
consistently showed that there was no significant difference in QT interval between 
smokers and non-smokers. Two studies found that the ST segment was decreased in 
chronic smokers versus non-smokers [214, 215]. Few studies have found that the Tp-Te 
interval, Tpe/QT ratio, and Tpe/QTc ratio were higher among smokers [216, 217], even 
after varenicline administration [218].  
Apart from the Zhang et al. study [219], none of these studies featured a quantitative 
method of smoking burden, such as cotinine, or an adjustment for clinically important 
covariates known to affect the baseline ECG (such as age, gender, body mass index, 
diabetes, coronary artery disease, etc). 
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Table 1.4 Major human studies on the chronic effects of smoking on atrial (A) and ventricular (B) electrocardiographic indices 
The effect mentioned of the ECG parameters is among smokers compared to non-smokers are mentioned. 
A) Atrial electrocardiographic indices
Ref Author, Year Chronic Smokers 
Non-
smokers P wave duration PR interval PR segment 
[220] Goldenberg, 2006 98 619 - Shorter - 
[221] Chatterjee, 1989 224 232 - Shorter - 
[212] Sharma, 2017 150 50 Shorter Shorter - 
[222] Baden, 1982 208 291 - Shorter - 
[223] Khan, 2011 75 30 - Shorter - 
[213] Swathi, 2015* 200 200 Shorter No difference - 
[214] Sandhya, 2015 64 63 - No difference - 
[224] Karapinar, 2010 30 30 No difference - - 
[225] Goette, 2007 46 49 No difference - - 
[226] Siddiqui, 2013 30 30 No difference No difference - 
[227] Venkatesh, 2010 50 50 No difference No difference - 
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B) Ventricular electrocardiographic indices
Ref Author, Year Chronic Smokers 
Non-
smokers QRS duration cQT / QT interval cJT interval 
[226] Siddiqui, 2013 30 30 Shorter No difference - 
[213] Swathi, 2015* 200 200 Shorter No difference - 
[227] Vanketash, 2010 50 50 Shorter No difference - 
[214] Sandhya, 2015 64 63 Shorter No difference Shorter ST 
[223] Khan, 2011 75 30 No difference - - 
[222] Baden, 1982 291 208 No difference No difference - 
[215] Devi, 2013 44 44 No difference No difference Shorter ST 
[219] Zhang, 2011 3306 2242 - No difference (adjusted and used cotinine) - 
[216] İlgenli, 2015 24 23 - No difference - 
[228] Karjalainen, 1997 10,717 - Decreased - 
[229] Ileri, 2011 30 30 - Increased - 
[212] Sharma, 2017 150 50 No difference Increased - 
* There were no statistical analyses performed.
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Acute exposure to smoking (nicotine and non-nicotine constituents) 
Apart from the case reports, the scarce literature on the acute effects of individual 
constituents of cigarette smoking on human in vivo ECG has mainly investigated nicotine 
and carbon monoxide. Acute carbon monoxide intoxication in children impaired 
ventricular repolarization with higher mean heart rate, QT dispersion, QTc dispersion, P 
dispersion, Tp-Te, QTc durations, Tp-Te dispersion, and Tp-Te/QT ratio compared to 
controls [230, 231]. However, it increased heart rate, ST-T wave changes, QTc dispersion, 
and TpTe dispersion in adults [232, 233]. There is also long-term increased risk of acute 
myocardial infarction in carbon monoxide poisoning [234]. Among 16 smokers 
undergoing electrophysiological study, exposure to cigarette smoke produced a statistically 
significant shortening of the sinus cycle length after chemical denervation of the sinus node 
with β-blockers and atropine [235]. In a single case report of mild nicotine toxicity, a young 
smoker presented with a typ1 Brugada pattern, raising the possibility of sodium channel 
blockade [236]. Nicotine has proved to be arrhythmogenic in animals and cell preparations; 
however, despite some case reports linking nicotine to atrial fibrillation in humans, these 
findings have not been confirmed in pharmacological studies of nicotine administered to 
human subjects [133]. 
There are very few human experimental studies that have investigated the acute 
effects of smoking on the ECG. In their analysis of 40 healthy male participants (20 
smokers), Akbarzadeh et al. discovered that heart rate, mean QT, and QTc dispersion 
increased 10 minutes after smoking a single cigarette [237]. In another study, 31 male 
smokers with atypical chest pain were screened with a treadmill exercise test, which 
revealed that the heart rate increased within 10 minutes and returned to baseline after 30 
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minutes. Smoking was also associated with increased ectopic beats in these patients on the 
24-hour Holter monitor [238]. On a signal averaged ECG, there was a minor lengthening 
of the filtered QRS duration among 15 long-term smokers after smoking two cigarettes 
[239].  
To date, the most comprehensive assessment of acute smoking’s impact on 
myocardial conduction was performed among 28 habitual smokers by Soad Bekheit and 
Evan Fletcher in 1976 using His bundle electrograms [240]. The following measurements 
were made from His bundle recordings in the control and “nicotine tracings” (immediately 
after the first puff, sequential atrial pacing at identical rates to the control tracings): intra-
atrial conduction time (P1A), A-V nodal conduction time (AH), His-Purkinje-system 
conduction time (HV), and total intraventricular conduction time (HS). They found that a 
few puffs of a cigarette increase the velocity of conduction and shortens the effective 
refractory period of the A-V node, whereas the conduction velocity in the His-Purkinje 
system is not affected [240]. However, these effects were not studied against those from 
nicotine exposure.  
Acute cigarette smoking increases efferent sympathetic nerve activity, primarily 
via the release of the catecholamines norepinephrine and epinephrine (Table 4). This 
catecholamine release increases myocardial work and oxygen consumption through an 
increase in blood pressure, heart rate, and myocardial contractility [19]. Overall, the vast 
majority of published evidence suggests that acute and chronic active and passive exposure 
to cigarette smoke generates marked disruptions in normal autonomic function 
characterized by increased SNS drive, reduced PNS modulation, and overall HRV. This 
phenomenon is partly attributable to a nicotine-induced up-regulation of catecholamine 
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release, generating potent acute and chronic effects on cardiovascular regulation through 
SNS activation [241]. 
Hypothesis 
Research Hypothesis:  
Nicotine in cigarette smoke alters myocardial conduction through β-adrenergic receptors 
Alternate Hypothesis: 
Non-nicotine constituents in cigarette smoke alter myocardial conduction though β-
adrenergic receptors and non-β-adrenergic pathways 
Central hypothesis: 
Aim 1 Explore the relationship between cigarette smoking and properties of myocardial 
conduction. 
Aim 2 Test the influence of catecholamines in the association between smoking and 
myocardial conduction. 
Aim 3 Acute effects of cigarette smoking and nicotine with and without β-blocker on 
electrocardiogram. 
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Ethical considerations 
The primary therapeutic use of nicotine is in treating nicotine dependence. 
Controlled levels of nicotine are given to patients through gum, dermal patches, lozenges, 
inhalers, or nasal and oral sprays to wean them off their dependence, increasing quitting 
success by 50%–70% [242]. In contrast to recreational nicotine products, which have been 
designed to maximize the likelihood of addiction, nicotine replacement products are 
designed to minimize addictiveness. Hence, physiological studies on the effects of chronic 
use of pure nicotine on humans are accompanied by the concern for potential addiction 
among non-smokers, or the tolerance or modulation of neural plasticity among habitual 
smokers. It is for this reason that there are no robust human physiological studies 
investigating the cause–effect relationship of prolonged exposure to pure nicotine. There 
are some studies on prolonged nicotine replacement therapies in smokers who have quit 
smoking, and in these studies, no adverse effects have been found when nicotine 
medication was administered for months to several years. Given the highly addictive nature 
of nicotine, these studies are more appropriately termed as acute or chronic exposure of 
nicotine in chronic tobacco (nicotine) users.  Therefore, to investigate the chronic effects 
of tobacco use on the electrocardiogram, we analyzed plasma/urine cotinine, a highly 
sensitive and specific marker of chronic nicotine exposure, as well as urinary 
catecholamines, in order to investigate the relationship between the sympathetic nervous 
system, smoking, and the electrocardiogram. Furthermore, to study the acute effects of 
smoking and nicotine with and without a β-blocker, we designed an open-label 2 x 2 
factorial experimental trial. 
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CHAPTER II  
CHRONIC EFFECTS OF CIGARETTE SMOKING ON ELECTROCARDIOGRAM 
Cigarette smoking, ECG and interaction with Atrioventricular nodal blockers  
Aim 1 Explore the relationship between cigarette smoking and properties of myocardial 
conduction 
Participants from NHANES database 
The availability of serum cotinine levels and digital ECG in the Third National 
Health and Nutrition Examination Survey (NHANES-III) provides a unique opportunity to 
examine the association between tobacco exposure and ECG parameters, in a large 
nationally representative human population.  The NHANES is a program of studies 
designed to assess the health and nutritional status of adults and children in the United 
States. The survey is unique in that it combines interviews and physical examinations. The 
survey examines a nationally representative sample of about 5,000 persons each year. 
These persons are located in counties across the country, 15 of which are visited each year. 
The NHANES interview includes demographic, socioeconomic, dietary, and health-related 
questions. The examination component consists of medical, dental, and physiological 
measurements, as well as laboratory tests administered by highly trained medical 
personnel. To produce reliable statistics, NHANES over-samples persons 60 and older, 
African Americans, and Hispanics. All participants visit the physician and all (but the very 
young) have a blood sample taken. Health interviews are conducted in respondents’ homes. 
Health measurements are performed in specially-designed and equipped mobile centers, 
which travel to locations throughout the country [243].
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Complete details about NHANES survey components, survey methodology, and sampling 
procedures are available from the Centers for Disease Control NHANES website [244]. 
Briefly, NHANES data are not obtained using a simple random sample.  Rather, a complex, 
multistage, probability sampling design is used to select participants representative of the 
civilian, non-institutionalized US population. The sample does not include persons residing 
in nursing homes, members of the armed forces, institutionalized persons, or U.S. nationals 
living abroad. A sample weight is assigned to each sample person. It is a measure of the 
number of people in the population represented by that sample person in NHANES, 
reflecting the unequal probability of selection, nonresponse adjustment, and adjustment to 
independent population controls. NHANES is designed to sample larger numbers of certain 
subgroups of particular public health interest. Oversampling is done to increase the 
reliability and precision of estimates of health status indicators for these population 
subgroups. 
Measures 
During the NHANES, individuals are asked questions related to smoking status, 
duration, and smoking-related behaviors.  Smoking status was assessed in the home, by 
trained interviewers using the Computer-Assisted Personal Interviewing System (CAPI). 
Participants responded to whether they currently smoke cigarettes daily, some days, or not 
at all. Participants were categorized as never-smokers (individuals who have smoked 
<100cig/lifetime), former smokers (having smoked >100cig/lifetime but do not currently 
smoke), and current smokers. Current smokers are further classified as daily smokers 
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(smoking cigarettes every day) and nondaily smokers (identifies as a smoker, but does not 
smoke cigarettes every day).  
Cotinine 
Measures such as cigarettes per day are imprecise indicators of tobacco smoke 
exposure because of variability in how smokers smoke their cigarettes. There is 
considerable individual variability in smoke intake, even by people smoking the same 
brand of cigarettes, and the cigarette design and how the cigarette is smoked influence toxic 
exposures. Therefore, the optimal assessment of exposure to tobacco smoke is the analysis 
of biomarkers for quantifying the systemic exposure of smokers to toxic constituents of 
smoke derived from tobacco use [245]. Nicotine measurement is highly specific for 
tobacco use or exposure (in the absence of nicotine medication use), but because of 
nicotine’s short half-life (2 h) the method is not recommended for general use. Nicotine is 
extensively metabolized to a number of metabolites by the liver, of which quantitatively, 
the most important metabolite of nicotine is the lactam derivative, cotinine. In humans, 
about 70–80% of nicotine is converted to cotinine. Cotinine is a highly specific and 
sensitive marker for tobacco use (in the absence nicotine medication use) and has the 
advantages of a fairly long half-life (16 h) [245]. Measuring cotinine in people’s blood is 
the most reliable way to determine exposure to nicotine for a marker for both active 
smoking, and as an index to Environmental Tobacco Smoke (ETS) exposure, or "passive 
smoking".  There is a high correlation among cotinine concentrations measured in plasma, 
saliva, and urine, and measurements in any one of these fluids can be used as a marker of 
nicotine intake. Cotinine concentrations tend to be higher (3–8x) in urine than in serum; 
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however, for studies requiring a quantitative assessment of exposure, plasma or serum is 
regarded as the fluid of choice. Therefore, serum is used for cotinine measurement in 
NHANES [243].  
Serum cotinine is measured by an isotope dilution-high performance liquid 
chromatography / atmospheric pressure chemical ionization tandem mass spectrometry (ID 
HPLC-APCI MS/MS). Briefly, the serum sample is spiked with methyl-D3 cotinine as an 
internal standard, and after an equilibration period, the sample is applied to a basified solid-
phase extraction column. Cotinine is extracted off the column with methylene chloride, the 
organic extract is concentrated, and the residue is injected onto a short, C18 HPLC column. 
The eluant from these injections is monitored by APCI-MS/MS, and the m/z 80 daughter 
ion from the m/z 177 quasi-molecular ion is quantitated, along with additional ions for the 
internal standard, external standard, and for confirmation. Cotinine concentrations are 
derived from the ratio of native to labeled cotinine in the sample, by comparisons to a 
standard curve [243].  
Electrocardiogram: Participants aged ≧ 40 years who attended the medical 
examination received a resting 12-lead ECG with a Marquette MAC 12-unit (Marquette 
Electronics, Inc., USA), and analyzed  using the NOVACODE ECG program, which 
classified the ECGs as per the Minnesota Coding (MC) System. Details of the ECG 
examination have been published previously [244]. Computerized automated analysis of 
the electrocardiographic data was performed with visual inspection of outlier values by a 
trained technician in a central ECG core laboratory (EPICARE Center at the Wake Forest 
School of Medicine, Winston Salem, NC). PR interval and P duration in lead II and global 
QRS duration and QT interval were automatically measured. PR segment was calculated 
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as the difference between PR interval and P duration. QT interval was Heart rate corrected 
using the Framingham formula (QTc), calculated as QT + 154 × (1 −60/HR) [246]. To 
measure the association between cotinine and the ECG intervals (PR interval, P duration, 
PR segment, QRS, QTc and JT) we divided them into three groups; >95th percentile (long), 
5 – 95th percentile (reference) and <5th percentile (short).  For the purpose of this analysis, 
we only included NHANES III participants who had good quality ECG recording and with 
no major ECG abnormalities including electrocardiographic evidence of myocardial 
infarction or ischemia as defined by Minnesota Electrocardiogram Classification, and 
available serum cotinine data, medical history, medication use, and anthropometric 
measurements. 
Covariates definitions: Since several ECG characteristics significantly differ by 
demographics, anthropometric features and cardiovascular risk factors and cardiac 
medications [247-252], we identified clinically important covariates to adjust for their 
effect on ECG parameters. Diabetes was defined as a fasting plasma glucose level of ≥126 
mg/dl, glycosylated hemoglobin A1C values ≥6.5, or a history of glucose-lowering 
medications. Hypertension was defined as systolic blood pressure of ≥130 mm Hg, 
diastolic blood pressure of ≥80 mm Hg, or use of blood pressure-lowering medications. 
Body mass index was computed as the weight in kilogram divided by the square of the 
height in meter, and obesity was defined as a body mass index of >30 kg/m2. Age, gender, 
race/ ethnicity, and smoking status were self-reported. Chronic Obstructive Pulmonary 
Disease (COPD) was defined as patients with a combination of asthma and emphysema. 
Alcohol consumption was assessed by the food frequency questionnaire. Participants 
reported the number of times that they drank beer, wine, and hard liquor in the past month, 
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and we categorized total alcohol consumption into 4 groups (0, 1–4, 5–13, ≥14 
drinks/month). Serum cotinine levels >15 ng/ml were used to categorize the participants as 
smokers, while those ≤15 ng/ml were categorized as non-smokers . 
Statistical analyses 
The ECG sampling weights were used in the analysis to account for the complex 
sampling design [253]. Categorical variables were reported as frequency and population 
percents, whereas continuous variables were recorded as geometric mean ± standard error 
for all demographic tables. Statistical significance in demographic tables was tested using 
survey weighted analysis; for continuous variables, t test or ANOVA, whereas Rao-Scott 
chi-square was used for categorical variables. Survey weighted Multinomial regression 
was used to calculate the odds ratios and 95% confidence intervals for the association 
between serum cotinine levels(> 15 ng/ml) and ECG intervals using the group 5 – 95th 
percentile as reference. A sensitivity analyses was carried out, and the overall results did 
not differ after excluding those participants who had serum cotinine > 15 ng/ml, and 
identified themselves as never-smokers (n=134) or ex-smokers (n=216). Multivariable 
adjusted models were constructed with incremental adjustments as follows: model 1 
adjusted for age, sex and race-ethnicity; and model 2 adjusted for model 1 covariates and 
heart rate, obesity, diabetes, hypertension, dyslipidemia, previous CVD, congestive heart 
failure, COPD and alcohol intake; and model 3 adjusted for model 2 covariates and β-
blockers, calcium channel blockers and anti-arrhythmic drugs. Model 4 was created based 
only on the baseline characteristics associated with the ECG intervals with p<0.10 
(Supplementary 2.1.2-2.1.7). The heart rate was not included in the model for QTc. We 
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also performed fully adjusted survey weighted linear regression between continuous 
cotinine levels and ECG intervals as continuous variables. We conducted subgroup 
analyses stratified by age (cut-off point by median - 59 years) and gender. A 2-sided p 
value of ≤0.05 was considered significant for main effects and for interactions. Data were 
analyzed using the survey procedures in SAS, version 9.4 (SAS Institute, North Carolina). 
Results 
A total of 5,633 study participants (mean age 59±13 years, 53% women, 48% non-
Hispanic white) were included in this analysis. A total of 1,580 (28%) participants were 
identified as smokers (serum cotinine levels > 15 ng/ml).  Smokers were more likely to be 
younger in age, men, with lower prevalence of dyslipidemia and β-blocker use and higher 
prevalence of COPD, higher resting heart rate and higher alcohol intake (Table 2.1.1). The 
5th and 95th percentiles of ECG variables are shown in Supplementary Table 2.1.1. and 
Supplementary Tables 2.1.2-2.1.7 represent the geometric mean and standard error for 
ECG variables, and represent the population percentages for categorical baseline 
characteristics.  
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Table 2.1.1 Baseline Participants Characteristics (Total N=5,653) 
Characteristic 
Smoker 
p-value 
No 
≤ 15 ng/ml 
n=4073, 72% 
Yes 
> 15 ng/ml 
n=1580, 28% 
Age (years)* 56.4 ± 0.44 53.4 ± 0.45 <0.001 
Women  2371 (59.1%) 629 (43.7%) <0.001 
Non-Hispanic White 2122 (82.2%) 738 (80.8%) 0.291 
Smoking status 
<0.001 
Never 2381 (56.1%) 134 (5.8%) 
Current 67 (1.6%) 1230 (78.4%) 
Past 1625 (42.3%) 216 (15.8%) 
Diabetes mellitus  479 (7.5%) 143 (7.0%) 0.630 
Hypertension  1427 (31.8%) 489 (28.8%) 0.167 
Dyslipidemia 1066 (29.3%) 308 (23.1%) 0.004 
Obesity  853 (18.0%) 233 (15.3%) 0.120 
COPD 263 (6.8%) 160 (10.8%) <0.001 
Heart rate (beats/minute) 67.6 ± 0.3 68.9 ± .04 0.012 
Prior cardiovascular disease 172 (3.2%) 67 (3.5%) 0.698 
Congestive Heart Failure 131 (1.8%) 54 (1.7%) 0.872 
Alcohol drinks per month 
0 2415 (50.7%) 762 (45.1%) 
0.003 
1-4 670 (18.0%) 253 (17.2%) 
5-13 440 (13.9%) 200 (13.3%) 
>13 539 (17.4%) 359 (24.4%) 
Β blockers 320 (8.2%) 87 (5.9%) 0.009 
Calcium channel blockers 333 (6.7%) 103 (6.0%) 0.453 
Antiarrhythmic drugs  34 (0.6%) 17 (1.5%) 0.129 
*Except for age (which is represented by geometric mean and standard deviation), all other variables are
represented as frequency and column percentages. 
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PR interval, P wave and PR segment 
In multinomial logistic regression models adjusted for demographics, smoking was 
associated with increased odds of short PR interval and short PR segment (p-value < 0.01) 
(Table 1.2). This association was not attenuated after further adjustment for CVD risk 
factors and AV nodal blockers, and was consistent in subgroups stratified by age and sex 
(Supplementary Table 2.1.8). No significant association was observed with smoking 
status and P wave duration. Follow-up linear regression analyses revealed a significant 
negative association between continuous cotinine levels and PR segment, but not with P 
wave and PR interval. According to model 4, the PR segment shortened by 0.554 ms per 
100 ng/ml increase in cotinine levels (Table 2.1.3). 
QTC interval, JT interval and QRS duration 
In fully adjusted multinomial regression models, serum cotinine was associated 
with short QRS and long JT (p-value <0.01), but not with abnormal QTc (Table 2.1.4). The 
association between smoking status and short QRS duration (<5th percentile) and long JT 
interval (>95th percentile) was consistent in subgroups stratified by age and sex 
(Supplementary Table 2.1.8). However, linear regression showed a significant 
association overall between continuous cotinine levels and QTc, but not with QRS duration 
and JT interval (Table 2.1.5). According to model 4, QTc shortened by -1.345 ms with 
every 100 ng/ml increase in cotinine. 
The effect of smoking status on baseline ECG (results from logistic regression) is 
shown in Figure 2.1.1, and the relationship between cotinine and ECG (results from linear 
regression) is shown in Figure 2.1.2. 
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Table 2.1.2 Association between smoking status and abnormal PR interval and its 
components 
ECG variables groups: Short (<5th percentile), reference (5-95th percentile) and Long 
(>95th percentile). N=5,653 
PR interval P duration PR segment 
Odds ratio 
(95% CI) 
p-
value 
Odds ratio 
(95% CI) 
p-
value 
Odds ratio 
(95% CI) 
p-
value 
Model 1* 
Short 1.63  (1.07, 2.48) 0.024
1.07  
(0.72, 1.57) 0.746
1.99  
(1.30, 3.05) 0.002
Reference - - - 
Long 0.73  (0.46, 1.16) 0.186
0.88  
(0.55, 1.40) 0.585
0.93  
(0.64, 1.37) 0.726
Model 2† 
Short 1.57  (1.02, 2.43) 0.042
1.10  
(0.75, 1.60) 0.639
1.95  
(1.28, 2.98) 0.002
Reference - - - 
Long 0.76 (0.49, 1.19) 0.231
0.91  
(0.57, 1.48) 0.715
0.96  
(0.65, 1.41) 0.825
Model 3^ 
Short 1.50  (0.95, 2.36) 0.081
0.98  
(0.67, 1.43) 0.914
2.00  
(1.25, 3.21) 0.004
Reference - - - 
Long 0.73 (0.47, 1.13) 0.159
0.91  
(0.57, 1.47) 0.706
0.96  
(0.64, 1.43) 0.841
Model 4Δ 
Short 1.58  (1.01, 2.48) 0.047
1.02  
(0.70, 1.49) 0.908
1.95  
(1.22, 3.10) 0.005
Reference - - - 
Long 0.74  (0.47, 1.15) 0.175
0.89  
(0.56, 1.41) 0.618
1.00  
(0.68, 1.47) 0.995
*Adjusted for age, sex and race-ethnicity
†Adjusted for variables in model 1 plus heart rate, obesity, diabetes, hypertension, dyslipidemia, previous 
cardiovascular disease, congestive heart failure, chronic obstructive pulmonary disease and alcohol intake 
^Adjusted for variables in model 2 plus β-blockers, calcium channel blockers and anti-arrhythmic drugs 
ΔAdjusted for variables found significantly associated with the ECG intervals: 
• PR interval: age, sex, previous cardiovascular disease, β-blockers, calcium channel blockers, heart rate
• P duration: age, sex, race-ethnicity, congestive heart failure, alcohol intake, β-blockers, calcium
channel blockers, heart rate 
• PR segment: age, sex, alcohol intake, calcium channel blockers, heart rate
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Table 2.1.3 Adjusted survey weighted linear regression between serum cotinine levels 
and PR interval, P duration and PR segment 
N=5,653 
PR interval (ms) P duration (ms) PR segment (ms) 
β-(95% CI) p-value β-(95% CI) 
p-
value β-(95% CI) 
p-
value 
Model 1* -0.832(-1.549, -0.116) 0.0237
-0.078
(-0.444, 0.288) 0.6709
-0.755
(-1.355, -0.154) 0.0149
Model 2† -0.593(-1.320, 0.134) 0.1074
-0.036
(-0.415, 0.343) 0.8490
-0.557
(-1.133, 0.019) 0.0579
Model 3^ -0.542(-1.262, 0.179) 0.1374
0.036 
(-0.362, 0.434) 0.8558
-0.578
(-1.135, -0.021) 0.0424
Model 4Δ -0.603(-1.301, 0.094) 0.0885
-0.008
(-0.391, 0.374) 0.9648
-0.554
(-1.090, -0.018) 0.043
*Adjusted for age, sex and race-ethnicity
†Adjusted for variables in model 1 plus heart rate, obesity, diabetes, hypertension dyslipidemia, previous 
cardiovascular disease, congestive heart failure, chronic obstructive pulmonary disease and alcohol intake 
^Adjusted for variables in model 2 plus β-blockers, calcium channel blockers and anti-arrhythmic drugs 
ΔAdjusted for variables found significantly associated with the ECG intervals: 
• PR interval: age, sex, previous cardiovascular disease, β-blockers, calcium channel blockers, heart rate
• P duration: age, sex, race-ethnicity, congestive heart failure, alcohol intake, β-blockers, calcium
channel blockers, heart rate 
• PR segment: age, sex, alcohol intake, calcium channel blockers, heart rate
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Table 2.1.4 Association between smoking status and abnormal corrected QT interval and 
its components 
ECG variables groups: Short (<5th percentile), reference (5-95th percentile) and Long 
(>95th percentile). N=5,653 
Corrected QT 
interval (ms) QRS duration (ms) JT interval (ms) 
Odds ratio 
(95% CI) 
p-
value 
Odds ratio 
(95% CI) 
p-
value 
Odds ratio 
(95% CI) 
p-
value 
Model 1* 
Short 1.23(0.87, 1.74) 0.243
1.46
(1.07, 1.99) 0.017
1.41
(0.99, 2.02) 0.060
Reference - - - 
Long 1.17 (0.71, 1.92) 0.544
1.04 
(0.69, 1.57) 0.842
1.50 
(0.97, 2.32) 0.071
Model 2† 
Short 1.17 (0.84, 1.63) 0.364
1.43 
(1.04, 1.98) 0.030
0.84 
(0.55, 1.27) 0.409
Reference - - - 
Long 1.15 (0.68, 1.95) 0.603
1.05 
(0.71, 1.57) 0.799
1.70 
(1.11, 2.61) 0.015
Model 3^ 
Short 1.01 (0.71, 1.46) 0.946
1.60 
(1.13, 2.26) 0.008
0.82 
(0.52, 1.27) 0.372
Reference - - - 
Long 1.29 (0.79, 2.11) 0.301
1.11 
(0.71, 1.73) 0.659
1.64 
(1.04, 2.57) 0.032
Model 4Δ 
Short 1.05 (0.71, 1.54) 0.813
1.39 
(1.02, 1.88) 0.035
0.82 
(0.53, 1.29) 0.392
Reference - - - 
Long 1.26 (0.79, 2.01) 0.328
1.09 
(0.73, 1.63) 0.682
1.81 
(1.13, 2.89) 0.013
*Adjusted for age, sex and race-ethnicity
†Adjusted for variables in model 1 plus heart rate (not for QTc), obesity, diabetes, hypertension, 
dyslipidemia, previous cardiovascular disease, congestive heart failure, chronic obstructive pulmonary 
disease and alcohol intake 
^Adjusted for variables in model 2 plus β-blockers, calcium channel blockers and anti-arrhythmic drugs 
ΔAdjusted for variables found significantly associated with the ECG intervals: 
• Corrected QT interval: age, chronic obstructive pulmonary disease, β-blockers, calcium channel
blockers 
• QRS duration:  sex, obese, chronic obstructive pulmonary disease, heart rate
• Uncorrected JT interval: age, sex, dyslipidemia, alcohol intake, heart rate, anti-arrhythmic drugs
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Table 2.1.5 Adjusted survey weighted linear regression between serum cotinine levels 
and corrected QT interval, QRS duration and JT interval 
N=5,653 
Corrected QT QRS duration JT interval 
β-(95% CI) p-value β-(95% CI) 
p-
value β-(95% CI) 
p-
value 
Model 1* -1.448(-2.375, -0.521) 0.0029
-0.251
(-0.489, -0.013) 0.0391
-1.198
(-2.043, -0.354) 0.0064
Model 2† -1.402(-2.347, -0.456) 0.0045
-0.184
(-0.414, 0.045) 0.1126
0.130 
(-0.327, 0.587) 0.5701
Model 3^ -1.112(-2.056, -0.169) 0.0218
-0.194
(-0.433, 0.044) 0.1079
0.189 
(-0.300, 0.679) 0.4414
Model 4Δ -1.345(-2.269, -0.421) 0.0052
-0.139
(-0.363, 0.086) 0.2205
0.233 
(-0.272, 0.738) 0.3579
*Adjusted for age, sex and race-ethnicity
†Adjusted for variables in model 1 plus heart rate (not for QTc), obesity, diabetes, hypertension 
dyslipidemia, previous cardiovascular disease, congestive heart failure, chronic obstructive pulmonary 
disease and alcohol intake 
^Adjusted for variables in model 2 plus β-blockers, calcium channel blockers and anti-arrhythmic drugs 
ΔAdjusted for variables found significantly associated with the ECG intervals: 
• Corrected QT interval: age, chronic obstructive pulmonary disease, β-blockers, calcium channel
blockers 
• QRS duration:  sex, obese, chronic obstructive pulmonary disease, heart rate
• Uncorrected JT interval: age, sex, dyslipidemia, alcohol intake, heart rate, anti-arrhythmic drugs
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Figure 2.1.1 The effect of smoking status on baseline ECG 
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Figure 2.1.2 Panel A shows the distribution of PR segment (ms) and QTc interval (ms) with cotinine levels 
(N=5,653). Panel B depicts the visual representation of corresponding progressive shortening of PR segment and QTc with increasing 
cotinine levels 
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Discussion 
In a large sample representative of the general US population, we found that higher 
levels of serum cotinine, a measure of tobacco exposure, was associated with extremely 
shortened PR interval, PR segment, QRS duration and extremely prolonged JT interval. 
We also found that, although cotinine-confirmed smoking did not associate with extreme 
changes in QTc, smoking severity as measured by serum cotinine had a significant negative 
linear relationship with QTc in the overall cohort.  
PR interval, P wave and PR segment 
There is a wide variation in the results of prior studies on the effects of tobacco 
exposure and PR interval and its components: PR segment and P duration [227, 254, 255]. 
However, studies with greater sample size consistently show smoking associated with 
shorter PR interval [212, 221, 223, 256-258]. Few studies showed increased P wave 
duration among smokers [222, 259] while other studies did not show any significant 
difference, [225, 227] or found a trend towards decreasing P wave duration with smoking 
[212]. We did not find any significant association between P wave duration and cotinine 
levels, suggesting less overt effects of tobacco exposure on atrial activity and atrial 
conduction. In a smaller cohort we recently revealed an inverse association between 
cotinine and PR interval, with evidence that this relationship was mediated via increased 
circulating dopamine[260]. In the present study, our observations spanned a large 
nationally representative cohort and further corroborate these findings that smoking 
accelerates atrioventricular conduction. 
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These findings are particularly important in light of emerging data on the prognostic 
value of short PR interval to predict atrial fibrillation [27] and cardiovascular mortality [26, 
29, 261]. Therefore, exposure to cigarette smoke (and perhaps nicotine specifically) 
accelerates atrioventricular conduction (as exhibited by short PR interval) and may 
possibly be a mechanism for increased risk of stroke and atrial fibrillation. 
QTc interval, JT interval and QRS duration 
Similar to the results of studies on PR interval and its components, there are mixed 
results on the effects of smoking on QTc and QRS duration [212, 228, 229, 262-265]. We 
were not able to find any study that explored the relationship between JT interval and 
smoking exposure. Only one study has investigated the effect of smoking, measured 
specifically by  cotinine, on JT interval. Like us, Zhang et al [219] used the NHANES III 
database, and among 7795 men and women found that in fully adjusted models QTc  was 
not associated with smoking and cotinine levels. At first this appears to conflict with the 
results of our study, but ancillary analyses  (not shown) revealed that this discrepancy stems 
from their use of quartiles instead of continuous QTc, and their restricting analyses to 
current smokers only. In addition, we also studied the association of cotinine with the 
components of QTc interval, and found that higher cotinine levels are associated with 
abnormally short QRS duration and long JT interval, but without any significant linear 
relationship with either subcomponents. 
The QT interval encompasses the time from the beginning of ventricular 
depolarization (QRS duration) and ventricular repolarization (JT interval) [170]. Prolonged 
QRS duration [182] and JT interval [31, 32] are well known predictors of mortality in the 
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general population, but the clinical implications for short QRS duration are not known.  
Sympathetic neural stimulation and systemic catecholamine release may underlie smoking-
induced acceleration of AV nodal conduction, while also explaining the shortening of QRS 
(ventricular depolarization)[63, 266, 267] and prolongation of JT (ventricular 
repolarization) [194, 268, 269]. Nicotine has been found to directly inhibit IKr and Ito
repolarizing currents [270]. Notably, nicotine also directly stimulates release of 
catecholamines from nerve terminals and the adrenal medulla [71, 271], effects that acutely 
augment IKs current and directly cause phosphorylation of its corresponding potassium 
channel to acutely accelerate repolarization via β-adrenergic receptors [272]. In addition to 
increased sympathetic tone and direct effects on ion channels, nicotine may also cause a 
pro-fibrotic state [273] and endothelial cell injury [274, 275].  Thus, nicotine is a 
particularly plausible culprit of these effects. Nevertheless, particulate matter and 
aldehydes within tobacco smoke may be key constituents and irritant reflexes or ischemia 
may be critical pathways through which smoking disrupts electrophysiologic homeostasis 
[276] 
Limitations 
It has not escaped our attention that a single measurement of serum cotinine may 
not fully reflect chronic smoking intensity. Moreover, because cotinine only reflects 
nicotine exposure, and by an imperfect proxy, smoking intensity, we are unable to assess 
relationships between other cigarette smoke constituents and cardiac electrophysiology. 
Although we have adjusted for several potential confounders, we recognize the possibility 
of residual confounding that is similar to other studies with a cross-sectional design. Also, 
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though the automated measurement of ECG intervals and segments, are routinely reported 
and can easily be calculated by the ECG systems, we did not perform manual 
measurements. Despite these limitations, this is the first study examining the association 
between serum cotinine, an objective measure of tobacco exposure, with PR and QT 
interval and their components. 
Conclusions 
We found in a large racially diverse sample of the US population, that elevated 
serum cotinine levels are independently associated with abnormally short PR interval, short 
PR segment, short QRS duration, and long JT interval. Additionally, increases in cotinine 
were associated with progressive shortening of QTc across all individuals. Collectively, 
our findings indicate that exposure to cigarette smoke increases risk for abnormally fast 
atrioventricular conduction and ventricular depolarization and abnormally long ventricular 
repolarization.  However, smoking induces a progressive prolongation of repolarization 
when also evaluating individuals within normal QTc ranges. These observations enhance 
our understanding of the relationship between smoking and cardiac arrhythmias and 
implicate specific pathophysiological mechanisms by which smoking increases 
cardiovascular morbidity and mortality, including for stroke and sudden cardiac death. 
More research is warranted to examine the specificity and selectivity of these effects and 
to delineate the direct contribution of specific tobacco constituents such as nicotine. 
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Effects of cigarette smoking on electrocardiogram mediated via catecholamines 
Aim 2 Test the influence of catecholamines in the association between smoking and 
myocardial conduction. 
This study was designed to study the effect of nicotine and cigarette smoke 
exposure on PR interval and its components in a cohort of patients with intermediate-to-
high CVD risk and to discern the role of sympatho-adrenal activity in these effects on 
atrioventricular conduction through analyzing urinary metabolites of nicotine and 
catecholamines (dopamine, norepinephrine, and epinephrine). 
Participants from Louisville Healthy Heart Study 
The study was approved by the Institutional Review Board at the University of 
Louisville. Individuals (>18 years of age) with intermediate to high CVD risk were 
recruited from the University of Louisville Hospital and affiliated clinic system between 
October 2009 and March 2011 as described previously [277]. All accessible patients 
visiting the clinics during this time period were pre-screened through a review of medical 
records prior to recruitment in order to exclude individuals that did not meet the enrollment 
criteria. In addition, persons unwilling or unable to provide informed consent or with 
significant and/or severe comorbidities were excluded. Exclusion criteria included: 
significant chronic lung, liver, kidney, hematological, or neoplastic disease, chronic 
neurological or psychiatric illness, chronic infectious disease such as HIV or hepatitis, 
severe coagulopathies, drug/substance abuse, and chronic cachexia. Pregnant women, 
prisoners, and other vulnerable populations were also excluded from the study. Patients 
who met the enrollment criteria and gave written consent were consented and administered 
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a questionnaire to provide demographic information and baseline characteristics. Medical 
records were reviewed for past medical history, vital signs and medication history. To 
reduce selection bias, all consecutive participants who were eligible for this study were 
recruited. For our analyses, only those patients with complete urinary biomarkers and ECG 
with normal sinus rhythm were included (Supplementary Figure 2.2.1).  
Electrocardiogram (ECG) measurement protocol 
Standard 12-lead ECGs with 2.5 seconds of each lead and 10 seconds of rhythm 
strip (lead II) from medical records were used for ECG analyses. The following ECG 
intervals were measured: P wave duration (from beginning to end of P) and PR interval 
from lead II (from beginning of P to beginning of Q) [26], QRS duration from lead V6 
(from beginning of Q to end of S) [278], and QT interval from V5 (from beginning of Q to 
end of T) [279]. The PR segment was calculated as the difference between PR interval and 
P wave duration. QT was also corrected using the Framingham formula [246] (Appendix 
A). All intervals were measured with electronic calipers and adjusted to scale by reported 
automated measures of RR (or heart rate). Two trained analysts (CA and AI) independently 
and manually measured each ECG interval (except RR) from the first 3 sinus beats. HRV 
parameters were derived from digital caliper measurements of all RRs in the rhythm strip. 
When average of any ECG interval for a given patient differed between the two analysts 
by >10%, both investigators re-measured that ECG interval independently. If the parameter 
remained >10% different between analysts, the analysts reviewed the ECG together and 
reached consensus on the appropriate measure. 
Urinary measurements 
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A spot urine sample was collected on the day of study enrollment. Urinary cotinine 
is a well-established metabolite for cigarette smoke exposure [245], and was measured by 
Ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) 
using D3-cotinine as an internal standard [280]. For UPLC-MS/MS analysis of dopamine, 
norepinephrine, epinephrine, and their metabolites (metanephrine, normetanephrine, 
vanillylmandelic acid, 3-methoxytyramine, homovanillic acid), urine samples were thawed 
on ice, vortexed and diluted 1:50 with 0.2% formic acid containing isotopic labeled internal 
standards. 1 µL of the mixture was analyzed on an UPLC-MS/MS instrument (ACQUITY 
UPLC H-Class system and Xevo TQ-S micro triple quadrupole mass spectrometer, all from 
Waters Inc., MA). Separation was performed on an Acquity UPLC HSS PFP (150 mm × 
2.1 mm, 1.8 μm) column (Waters Inc., MA) with a binary gradient comprised of 0.2% 
formic acid (Solvent A) and methanol (Solvent B). Three multiple reaction monitoring 
(MRM) transitions were set up for each sample: one for quantification, one for 
confirmation, and one for labeled internal standard. At least 12 data points were collected 
for each peak. Analytes were quantified using peak area ratio based on 8 point-standard 
curves run before and after the urine samples. The concentration values of analytes were 
normalized to creatinine level which was measured on a COBAS MIRA-plus analyzer 
(Roche, NJ) with Infinity Creatinine Reagent (Thermo Fisher Scientific, MA). 
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Statistical Analysis 
Baseline subject characteristics were summarized by smoking status. Categorical 
characteristics, frequencies and percentages are reported along with Chi-square test p-
values, which were used to compare distributions across study groups. In addition to visual 
inspection of histograms, Shapiro-Wilk tests were conducted for continuous characteristics 
to determine if the characteristics were approximately normally distributed. Mean and 
standard deviation are reported for continuous characteristics with a normal distribution, 
whereas median and interquartile range are reported for continuous characteristics with a 
skewed distribution, and the study groups were compared by the appropriate statistical test 
based on normality. P-values were derived from Student’s t-tests for study group 
comparisons of normally-distributed variables, whereas Mann-Whitney tests were used for 
variables lacking a normal distribution. The urinary metabolites (cotinine, dopamine, 
norepinephrine and epinephrine and their daughter metabolites) were log-transformed 
because their distribution was skewed. We tested the associations between ECG parameters 
and urinary metabolites by linear regression. ECG parameters were dichotomized by their 
median levels into high- and low-value groups. Baseline characteristics associated with 
ECG variables in bivariate analyses (with p<0.01) were used to build fully adjusted models 
using linear regression analyses. Smoking status was determined as reported by the 
participant (active smoker, former smoker or non-smoker) and by urinary cotinine levels 
of 50 ng/ml [245]. Finally, mediation was assessed by the bootstrapping technique and 
macro put forth by Preacher and Hayes [281]. Statistical analyses were performed using 
Statistical Package for Social Sciences (SPSS) software (version 24, SPSS, Inc, Chicago, 
IL, USA). 
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Results 
Baseline characteristics 
A total of 136 participants were in normal sinus rhythm and had ECGs and urinary 
metabolites available. The participants were approximately evenly split by gender (male 
n=72, 53%), about half of all participants were Caucasians (n=77, 57%), and mean age was 
52 years. Participants had a high prevalence of CVD risk factors; with a majority diagnosed 
with hypertension (n=119, 87%) and/or on β-blockers (n=98, 73%) (Table 2.2.1).  Several 
of the participants were diagnosed with diabetes (n=43, 32%) or prior myocardial infarction 
(n=62, 46%), and/or were taking calcium channel blockers (n=32, 24%) or β-blockers 
(n=98, 73%). The relationship of baseline characteristics with dichotomized PR interval, P 
duration, and PR segment are shown in Supplementary Table 2.2.1. Mean age and 
proportion of females were significantly higher among individuals in the upper stratum for 
PR interval, whereas mean BMI, or proportion of participants who were female, 
hypertensive, or taking calcium channel, ACE, or angiotensin receptor inhibitors were 
higher among those with longer P duration. Conversely, only the number of participants 
on diuretics were higher among those with longer PR segment 
70 
Table 2.2.1 Baseline characteristics 
All patients Current smoker 
N=136 
Yes 
(N=53, 
39%) 
No 
(N=83, 
61%) 
p value 
Age (years)* 52, 10 53, 10 50, 9 0.05 
BMI (kg/m2)* 33, 8 34, 8 31, 7 0.06 
SBP (mm Hg)* 133, 23 132, 22 136, 24 0.15 
DBP (mm Hg)* 81, 13 80, 11 81, 16 0.37 
Heart rate (beats/min)* 73, 15 74, 15 73, 15 0.99 
Male gender 72, 53% 43, 52% 30, 57% 0.58 
Caucasian 77, 57% 46, 55% 31, 59% 0.73 
Hypertension 118, 87% 74, 89% 45, 85% 0.47 
Prior MI 62, 46% 40, 48% 23, 43% 0.58 
Diabetes 43, 32% 28, 34% 15, 28% 0.51 
Stroke 23, 17% 14, 17% 10, 19% 0.77 
Arrhythmia 45, 33% 28, 34% 17, 32% 0.84 
Β blocker 98, 73% 65, 78% 34, 64% 0.07 
CCB 32, 24% 24, 29% 8, 15% 0.06 
ACEI or ARB 89, 66% 54, 65% 35, 66% 0.91 
Statin 84, 62% 55, 66% 30, 57% 0.26 
Aspirin 81, 60% 49, 59% 33, 62% 0.71 
Diuretics 58, 43% 38, 46% 20, 38% 0.35 
Abbreviations: BMI -  Body mass index, SBP- Systolic Blood Pressure, DBP – Diastolic Blood 
Pressure, MI – Myocardial Infarction, CCB – Calcium Channel Blocker, ACEI - Angiotensin-Converting 
Enzyme Inhibitor, ARB - Angiotensin II Receptor Blocker 
For each variable counts and column percentage has been reported except for where indicated * where the 
mean and standard deviation (SD) are reported 
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Smoking status and catecholamine levels 
Overall smoking prevalence was 61% (n=83) by self-report and 46% when defined 
by urinary cotinine >50 ng/ml (Cohen’s κ=0.79, p<0.001 for agreement between these 
measures). Three participants self-reported as never smokers had urinary cotinine levels 
>50 ng/ml and two who self-reported as active smokers had urinary cotinine levels of £50 
ng/ml (Supplementary Table 2.2.2). None of the cohort characteristics were significantly 
different between active smokers and the rest of patients; although trends of higher age, 
BMI, and use of calcium channel and/or β-blockers was observed among smokers. All 
urinary metabolites (cotinine, dopamine, epinephrine and norepinephrine) were higher 
among current smokers vs never-smokers. None of the catecholamines were different 
between current smokers and ex-smokers (p>0.05); however, catecholamines were higher 
in the high-cotinine group relative to the low-cotinine group (Supplementary Table 2.2.3 
A).  
Supplementary Table 2.2.4 shows that cotinine was significantly associated with 
dopamine and norepinephrine, but not with epinephrine. We also explored the possible 
effect of cotinine on catecholamine metabolism by the association of cotinine and the 
daughter metabolites and their ratios. Each catecholamine’s intermediate metabolite, and 
none of the final metabolites, had a significant positive association with cotinine. Among 
the ratio of intermediate/parent metabolites, cotinine associated positively with 3-
methoxytyramine/Dopamine (an index of catechol-o-methyltransferase activity) and 
inversely with vanillyl mandelic acid/normetanephrine and vanillyl mandelic 
acid/metanephrine (both indices of MOA activity). 
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Association of cotinine with P- and PR-parameters 
Smokers did not differ from non-smokers in proportion of participants within strata 
of long or short P duration, PR interval, or PR segment.  Distribution of participants into 
high- or low-PR or P-duration parameters also did not differ by cotinine dichotomization 
(Supplementary Table 2.2.3 B). When analyzed as a continuous variable, cotinine was 
significantly higher among participants with short PR segment compared to those with long 
PR segment (p=0.03). PR interval also showed a similar trend (p=0.06), whereas cotinine 
did not differ between participants with long vs. short P duration (p=0.25) (Table 2.2.2). 
Among all participants, cotinine had a significant negative association with PR interval and 
PR segment (but not with P duration) in linear regressions, even after adjusting for age, 
gender and heart rate (Table 2.2.3). Figure 2.2.1 shows the scatterplot distributions of PR 
interval, P duration, and PR segment across log-transformed urinary cotinine levels 
normalized by creatinine.  Cotinine was not significantly associated with other ECG 
parameters, including QRS duration, QT interval and corrected QT, in unadjusted and 
adjusted models (Supplementary Table 2.2.5). 
Catecholamines and PR interval 
All three catecholamines were significantly elevated among participants with short 
P duration relative to those with long P duration (Table 2.2.2). Dopamine was also elevated 
among those with shorter PR-interval relative to those with longer PR-interval (p=0.01). 
Dopamine showed a trend of being higher among patients with short vs. those with long 
PR-segment. The adjusted linear regression showed all three catecholamines inversely 
associated with PR interval (p<0.05), none of the catecholamines associated with P 
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duration, and only dopamine inversely associated with PR segment (Supplementary 
Table 2.2.6).  
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Table 2.2.2 Comparison of creatinine-normalized urinary biomarkers (median [interquartile range]) among participants dichotomized 
into high and low atrial and atrioventricular conduction parameters 
N=136 
All patients 
PR interval P wave duration PR segment 
≤ 163.32 
ms 
> 163.33 
ms 
p 
value 
≤ 104.73 
ms 
> 104.74 
ms 
p 
value ≤ 55.20 ms > 55.21 ms
p 
value 
Cotinine (ng/g) 23.1 [1.6 - 794.1] 
30.6 
[1.5 - 948.4] 
23.0 
[1.8 - 647.7] 0.45
238.3 
[2.3 - 102.5] 
5.8 
[1.4 - 627.1] 0.08
130.7 
[2.4 - 1070.1] 
9.5 
[1.2 - 591.3] 0.03
Dopamine 
(μg/g) 
165.4 
[127.6 - 
214.1] 
179.8 
[142.3 - 
228.5] 
150.6 
[119.7 - 
189.5] 
0.01 
180.1 
[142.0 - 
234.7] 
111.6 
[180.3 - 
168.8] 
0.01 
168.8 
[140.7 - 
219.8] 
160.5 
[119.7 - 
204.9] 
0.07 
Epinephrine 
(μg/g) 
4.7 
[2.4 - 7.9] 
5.6 
[2.9 - 8.6] 
8.6 
[4.1 - 7.5] 0.23
5.9 
[3.5 - 9.8] 
3.9 
[1.7 - 6.4] 0.01
5.2 
[2.1 - 8.9] 
4.2 
[2.5 - 7.5] 0.75
Norepinephrine 
(μg/g) 
37.2 
[26.0 - 53.3] 
36.7 
[26.9 - 52.6] 
38.0 
[22.9 - 56.4] 0.86
41.2 
[30.7 - 54.5] 
31.9 
[22.1 - 52.3] 0.03
36.4 
[28.0 - 51.7] 
37.5 
[22.7 - 55.6] 0.75
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Table 2.2.3 Estimated effects (β-coefficients) of an increase in cotinine on PR interval, P wave, and P segment, with corresponding P-
values, from unadjusted and adjusted linear regressions.  
Urinary cotinine was log-transformed. N=136 
PR interval P duration PR segment 
b p value b p value b p value 
Unadjusted Cotinine -2.38 0.04 0.33 0.73 -2.70 0.03 
*Adjusted Cotinine -2.67 0.05 0.87 0.32 -2.10 0.04 
* model adjusted for age, body mass index, and gender (PR interval); BMI, SBP, DBP, gender, hypertension, CCB, and ACEI, and ARB (P duration); or BMI, β-
blocker, and diuretics (PR segment). 
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A    B  C 
Figure 2.2.1 Scatterplot and linear relationships of (A) PR interval, (B) P wave and (C) PR segment with log transformed urinary 
cotinine levels 
P values represent unadjusted linear regression.N=136 
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Mediation analyses 
In linear regression analyses cotinine was inversely associated with PR segment 
and PR interval, and dopamine was the only catecholamine significantly associated with 
both PR segment and PR interval (inversely in both cases). We therefore conducted 
mediation analyses to determine whether dopamine mediated the association between 
cotinine and PR segment and also between cotinine and PR interval. Figure 2 shows the 
relationship between cotinine and dopamine (path a); the relationship between dopamine 
and PR interval/segment (path b); and the total effect of cotinine on PR interval/segment 
(path c). The total effect (c) is the sum of direct (c’) and indirect (ab) effects. The direct 
effect is the relationship between cotinine and PR interval/segment while controlling for 
mediators. The indirect effect represents the mediated effect. Mediation analysis showed 
that dopamine completely mediated the association of cotinine with PR interval (c’, 
p=0.46) and PR segment (c’, p=0.09). Specifically, the indirect effect (path a × b) of 
cotinine on PR interval through dopamine had a point estimate of -1.23 and an upper and 
lower 95% CI of -2.90 and -0.26; and the indirect effect (path a × b) of cotinine on PR 
segment through dopamine had a point estimate of -0.52 and an upper and lower 95% CI 
of -1.57 and -0.08 (Figure 2.2.2). 
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Figure 2.2.2 Mediation analyses of cotinine, dopamine, and PR interval and PR segment 
N=136 
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Discussion 
The effects of smoking on atrial and atrioventricular nodal conduction velocity and 
their underlying mechanisms are currently unknown. To address this gap in knowledge, we 
measured PR interval, P wave duration, and PR segment from lead II of a 12-lead EKG, 
urinary catecholamines, and nicotine and its metabolites in a cohort of 136 participants 
with intermediate-high cardiovascular risk. We report three major findings from this study. 
First, cotinine had a significant inverse association with PR interval and PR segment, and 
not with P wave duration in adjusted linear regression models. Second, urinary dopamine 
was inversely associated with PR interval and both its components (PR segment and P 
duration), while epinephrine and norepinephrine did not associate with PR segment. Third, 
mediation analyses indicate that dopamine may primarily account for the association 
between cotinine and shortening of both PR interval and segment. Together, these findings 
suggest smoking may increase cardiovascular morbidity and mortality through nicotine-
associated increases in catecholamine release and downstream modulation of 
atrioventricular conduction. 
Nicotine and PR interval and its components 
Previous work on the chronic effects of smoking on PR interval has produced mixed 
results. Some studies found short PR interval at baseline among chronic smokers vs non-
smokers [212, 221, 257], while others found no difference [254, 282]. Similarly, a few 
studies showed increased P wave duration among smokers [222, 259], while other studies 
did not show any significant difference [225, 227] or found a trend towards decreasing P 
wave duration with smoking [212]. There are several reasons for the wide variation in the 
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results of prior studies; 1) small sample size, 2) insufficient consideration for the role of 
the components of PR interval, and 3) inadequate assessment of nicotine exposure and its 
potential impact. To the best of our knowledge, to date, no previous study investigated the 
effects of nicotine exposure on PR interval and its components in humans. This is 
particularly important in light of recent findings that short PR interval associates with 
increased risk for atrial fibrillation and cardiovascular mortality [26, 29, 261, 283].  Beyond 
overall cardiovascular mortality, smoking also associates with increased risk of atrial 
fibrillation through unknown mechanisms [284]. Thus, by demonstrating that exposure to 
cigarette smoke (and perhaps nicotine specifically) accelerates atrioventricular conduction, 
our findings provide further insight into how smoking may confer cardiovascular risk, 
including risk for atrial fibrillation. 
In the present study, cotinine inversely associated with PR interval and PR segment, 
indicating that increased cigarette smoke exposure accelerates atrioventricular conduction. 
PR interval is mainly influenced by the sum of atrial activity and atrioventricular nodal 
conduction [170]. Atrial pathology usually results in prolonging (rather than shortening) of 
PR interval, whereas shortening of PR interval is likely a result of accelerated 
atrioventricular nodal conduction. Hence, it is plausible from our results that chronic 
nicotine exposure expedites atrioventricular nodal conduction. Moreover, because P wave 
duration was not associated with cotinine, our findings suggest nicotine has limited effects 
on atrial conduction.  Using our linear regression coefficient, we found that each 100 ng/ml 
cotinine is associated with a 12.3-ms decrease in PR interval and 9.7-ms decrease in PR 
segment. 
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Cotinine and catecholamines 
Cigarette smoking and nicotine result in increased central and peripheral sympatho-
adrenal activation. The activation of nicotinic acetylcholine receptors in the adrenal 
medulla leads to increased catecholamine levels [285]. We found urinary dopamine and 
norepinephrine (but not epinephrine) were significantly higher among smokers and those 
with higher cotinine, suggesting smokers have chronically increased sympathetic neuronal 
activity (norepinephrine), but similar adrenal medullary hormone secretion (epinephrine). 
Interestingly, we also found that the intermediate metabolites of all three catecholamines 
significantly associated with cotinine, but not with the final product, and there was a 
negative association between cotinine and the ratio of the final and intermediate metabolite. 
This suggests cigarette smoking is associated with increased synthesis of dopamine and 
norepinephrine and at the same time decreases the catabolism of the intermediate 
metabolites of all three catecholamines. This corroborates the findings of several other 
studies that showed cigarette smoking inhibits the activity of MOA [286, 287]; an enzyme 
primarily responsible for catabolism of the intermediate metabolites of norepinephrine and 
epinephrine to their final metabolites.   
There are several mechanisms through which nicotine can possibly increase 
atrioventricular nodal conduction velocity. Nicotine stimulates sympathetic 
neurotransmission via activation of nicotinic acetylcholine receptors localized on 
peripheral postganglionic sympathetic nerve endings and the adrenal medulla which in turn 
cause catecholamine release [91, 285]. Catecholamines mediate positive chronotropic, 
inotropic, dromotropic, and bathmotropic effects (i.e., increased rate, force conductivity 
and excitability) [288]. Furthermore, evidence from animal models and ex-vivo studies 
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suggests nicotine may also directly cause endothelial cell injury [275], a pro-fibrotic state 
[273], and inhibition of cardiac A type potassium channels [85].  
The mediation analysis is a novel component to our study that reveals, among 
catecholamines, dopamine fully mediates the effect of cotinine and shortening PR 
interval/segment. The positive dromotropic effects of dopamine accelerate atrioventricular 
nodal conduction [289, 290], thereby expected to shorten the PR interval/segment without 
affecting P wave duration, as seen in our study.  
Cotinine was even associated with altered metabolism of the three catecholamines 
(ratio of metabolite/parent). The positive association of cotinine with 3-
methoxytyramine/Dopamine ratio suggests smoking increases dopamine synthesis and/or 
systemic secretion and, in compensation, also increases catechol-O-methyltransferase 
(COMT) activity.  Also, cotinine’s inverse association with Vanillylmandelic 
acid/Normetanephrine and Vanillylmandelic acid/Metanephrine suggest that smoking 
decreases MAO activity, consistent with observations of decreased MAO-B in the 
amygdalae of smokers and the antidepressant effects of nicotine [291, 292]  
Catecholamines and PR interval 
Interestingly, in our study only dopamine and not epinephrine and norepinephrine 
were associated with PR interval and PR segment. As all catecholamines are known to 
exert a dromotropic effect, plausible reasons for our finding include: 1) short and long term 
stress (smoking) disproportionately affect circulating dopamine relative to norepinephrine 
and epinephrine [293], perhaps secondary to nicotine-mediated declines in dopamine 
uptake [294];  2) cigarette smoking and/or nicotine cause an immediate surge in dopamine 
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from neuronal [9], that may cross the blood brain barrier to increase circulating dopamine; 
3) as the precursor of both epinephrine and norepinephrine, dopamine may have less
temporal variability, making it a more stable marker of chronic SNS activation; and 4) at 
low pathophysiological stress levels, dopamine may have higher affinity than epinephrine 
and norepinephrine for β-1- and β-2- adrenergic receptors, which modulate dromotropy in 
the atrioventricular node [295] .  
Other ECG parameters 
We did not observe any association of smoking status or cotinine with QRS, QT or 
cQT and. Previous studies in this area have yielded mixed results, including QT 
prolongation [229, 262, 263], QT shortening [228], or no relationship [219] with smoking. 
Limitations 
While this is the first known investigation of the influence of catecholamines in 
nicotine-mediated alterations in cardiac conduction, the sample size is limited and 
participants were drawn at random from the outpatient clinic setting with intermediate to 
high cardiovascular risk. Thus, we might have missed significant associations between 
cotinine and other parameters (e.g., P-wave duration) due to insufficient statistical power. 
Additionally, ECGs were obtained retrospectively from medical records and not on the day 
of enrollment. The median and interquartile range of number of days from study enrollment 
(urine sample collection) and ECG was 79 [20 – 320] days. We did not collect data on time 
of last cigarette/nicotine exposure and states that may affect catecholamines (stress, noise, 
discomfort, body position, consumption of food, caffeinated beverages and drugs).   
84 
Nevertheless, we used urinary analytes (cotinine and catecholamines) that are established 
markers for chronic nicotine and sympatho-adrenal activation and are unlikely to exhibit 
large acute variation in the outpatient clinic setting from which this cohort was derived. 
We did not collect 24-hour urine to account for diurnal and intra-individual variation in 
catecholamines [296]; however, summative analysis of 24-h catecholamine production 
may mask elevations due to dilution. Importantly, a HRV parameter (RMSSD: square root 
of the mean of squared differences of successive NN intervals), when dichotomized, tended 
to inversely associate with urinary norepinephrine and dopamine (r= -0.13, p=0.10 for 
both), suggesting concordance between measures of sympathetic activity in both ECG and 
subsequent urine samples. Although most participants were on β-blockers, prevalence did 
not significantly differ by cotinine strata, and PR and P wave durations did not differ by β-
blocker use. This latter point accords with observations that β-blockers do not alter resting 
PR interval whereas they partially attenuate PR and RR interval shortening during exercise-
induced sympatho-excitation [297, 298]. Additionally, we were unable to assess 
associations between other cigarette components or smoking habits (e.g., frequency) and 
cardiac electrophysiology. Other constituents within tobacco smoke (e.g., particulate 
matter and aldehydes) have been shown to alter autonomic balance and may thus plausibly 
alter catecholamine synthesis, secretion, and metabolism. Finally, smoking and nicotine 
can affect myocardial conduction velocity through induction of cardiac remodeling, 
oxidative stress, and/or ion channel dysfunction, which were not assessed in this study and 
may occur independent of sympathetic activation. Nevertheless, sympathetic activation can 
induce all three of these pathogenic processes [299] and may thereby indirectly mediate 
atrioventricular conduction defects. 
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Conclusions 
Collectively, our findings suggest that exposure to cigarette smoke accelerates 
atrioventricular conduction and that dopamine mediates these effects. More research is 
warranted to examine the specificity and selectivity of these effects and to delineate the 
direct contribution of nicotine. These observations identify a pathway by which smoking 
may increase risk for cardiovascular morbidity and mortality. 
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CHAPTER III  
ACUTE EFFECTS OF NICOTINE AND CIGARETTE SMOKING ON 
ELECTROCARDIOGRAM  
Aim 3 Acute effects of cigarette smoking and nicotine with and without β-blocker on 
electrocardiogram. 
Cigarette smoking has acute deleterious effects on the cardiovascular system, 
resulting in increased incidence of coronary artery disease, atrial and ventricular 
arrhythmias and sudden cardiac death among smokers [300, 301]. Despite, a strong dose-
response relationship between cigarette smoking and CVD, it remains unclear which 
tobacco smoke constituents and biological pathways mediate this increased risk. The main 
addictive component in cigarette smoke, nicotine, has been implicated as possibly the 
major mediator of acute cigarette smoke induced ANS dysregulation of the heart via 
increased sympathetic nerve activity and multiple downstream mechanisms [133]. 
Imbalance within the ANS is increasingly recognized as a major culprit of CVD. Indeed, 
both acute and chronic activation of the sympatho-adrenal  system, promotes 
cardiovascular dysfunction and disease, including arrhythmia, hypertension, heart failure, 
myocardial infarction, and ischemic stroke [302, 303]. The rising popularity of ENDS, and 
the enhanced nicotine dose of some ENDS devices relative to conventional smoking [304], 
have created an imperative to determine the cardiovascular effects of nicotine and the role 
of autonomic imbalance within them. 
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The ECG is a widely available, inexpensive, non-invasive, routine method of 
measuring electrical activity of the heart, and can be used to screen high risk populations 
and identify ad predict CVD. Several ECG parameters have also been used clinically to 
assess cardiovascular autonomic dysfunction as a diagnostic and prognostic factor. There 
is now abundant evidence that acute ANS imbalance has profound effects on 
electrophysiology [305, 306]. Further, acute variations in hemodynamics [307] and 
conventional ECG parameters, including dispersion of ECG intervals and amplitudes, may 
result from acute ANS imbalance and, when frequent, carry worse long term prognosis 
[308-310]. Additional parameters have recently been added to the repertoire of ECG 
indices that reliably predict cardiovascular morbidity and mortality (i.e., P wave amplitude, 
PR interval, and JT interval) [26, 30, 283, 311-313].  
Despite known cigarette induced acute ECG changes and powerfully predictive 
value of ECG changes for future CVD events, no prior study has systematically 1) 
evaluated the acute temporality of the acute electrocardiographic effects of smoking, and 
2) compared these with nicotine alone, and 3) explored the potential underlying
mechanisms. To the best of our knowledge, this is the first report on the immediate effects 
of cigarette smoking and nicotine on ECG morphologic endpoints. We therefore conducted 
an open label 2 x 2 factorial experimental trial to study the acute effects of smoking and 
nicotine, with and without β-blocker. 
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Participants and setting of the experimental trial 
Study design 
Participants were recruited via online and flyer advertisements in the public areas 
city of Huntington, WV. The study enrolled healthy adult male and female smokers, aged 
18–65 years, who had smoked at least 10 cigarettes/day for at least one year prior to the 
trial. Eligible participants had to weigh at least 55 kg and have a body mass index (BMI) 
within the range 17.5–30.0 kg/m2. Females who were pregnant or breast feeding, 
vulnerable population (such as patients with mental illness, prisoners etc), and participants 
with any medical illness requiring routine medications were excluded from the trial. 
Participants were screened over the phone call before entering the trial. The study design 
is shown in Supplementary Figure 3.1 A 
Participants 
The study was approved by the Institutional Review Board at Marshall University. 
Each participant signed an informed consent before inclusion in the study. Twenty healthy 
smokers (65% men; 37±13 years of age; body mass index, 28±5 kg/m2) and ten healthy 
non-smokers smokers (70% men; 28±5 years of age; body mass index, 26±3 kg/m2) were 
included in the study. All of the smokers were regular habitual cigarette smokers (22±8 
cigarettes per day for 21±12 years). The baseline characteristics along with details of 
smoking history and cigarette are provided in Supplementary Table 3.1. Except for one 
smoker (who used rescue inhaler occasionally for well controlled mild asthma), no other 
participant had any known medical illness nor routine medication use (including birth 
control pills). All subjects were at least high school graduates. 
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Study visits and exposures 
All participants had abstained from food, coffee, and tobacco overnight before each 
study visit. Each smoker completed two-day visits, where on their first day they smoked 
single preferred brand of Combustible Cigarette (Cig) in their usual manner, and second 
day they were administered 4 mg of nicotine from Nicotine mouth Spray device (NicS) 
designed to mimic the acute nicotine delivery of cigarettes. Ten of the twenty smokers were 
randomly invited for two additional visits, where the exposures remained the same (i.e. 
preferred single combustible cigarette smoke on day 3 and 4 mg nicotine spray on day 4), 
but were pre-treated with 80 mg oral propranolol (non-selective b-blocker) for two hours 
prior to the start of the study (BB-Cig and BB-NicS). The oral propranolol was 
administered by physician, and participant’s vitals were closely monitored during the day 
3 and 4. Ten of the twenty smokers also completed a fifth visit to serve as controls, where 
they simulated smoking by inhaling through their unlit cigarette (“Sham”), for the similar 
duration of smoking period on Cig. 
The nicotine mouth spray device (Nicorette oromucosal nicotine spray, 1 mg/spray, 
McNeil AB) consists of a plastic bottle with 13.2 ml of a clear to slightly opalescent liquid 
with a mint flavor. After priming, one depression of the spray nozzle delivers a metered 
dose of 1 mg of nicotine in 0.073 ml of a 10% ethanol-in-water solution. The spray liquid 
also contains very small amounts of levomenthol (0.7 mg/spray dose) and other flavorings 
(less than 0.3 mg/spray dose) [314]. The 4 mg of nicotine was administered by study 
personnel by pressing the nozzle four times in rapid succession, directed straight into the 
participant’s mouth. Participants were advised to avoid respiring during, and swallowing 
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immediately after, administration of the spray. The dose-concentration curve from the oral 
spray (Cmax 9.1 ng/ml and Tmax, 10 minutes, T ½ 2.6 hr) [314], mimics that of smoking 
cigarette with  about 1 mg of nicotine content (Cmax 11.9 ng/ml and Tmax, 8 minutes, T 
½ 2.5 hr) [315]. 
Procedures 
All study visits were separated by washout periods of at least 24 hours, and were 
started between 8 AM and 10:00 AM. After arrival to the research clinic, and obtaining 
informed consent, each participant completed a detailed health and tobacco use 
questionnaire. Height and weight were measured. There was a rest of 5 minutes before each 
blood pressure measurement and ECG recording session. Pre and post exposure blood 
pressure were measured in sitting position using a validated automated monitor, in 
accordance with the guidelines [316]. Pre and post exposure serum and plasma were also 
collected, and stored at −20 °C until analysis (except for on Sham smoking day). A standard 
continuous 12 lead ECG was recorded (Cardio Card, Nasiff Associates, Central Square, 
NY), using as per guidelines [317], for 5 mins indoor while supine (pre-exposure), 20 mins 
outside while seated (during exposure) and 5 mins indoors while supine (post-exposure). 
The exposures were always performed while seated in the same spot; which was outside in 
an open public area, (200 feet away from the research building); which was not a designated 
public smoking place and away from main road traffic area. Supplementary Figure 3.1 B 
and Appendix B show the schematic timeline of the study day protocol. 
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ECG and HRV analyses 
Data from Lead II was extracted and each beat was analyzed using the 
commercially available software LabChart/ECG and HRV Analysis Add-On (version 8.0; 
ADInstruments, Colorado Springs, CO, USA) (Appendix C). The artifacts were identified 
and removed from the analysis using the ECG Beat Classifier; which measures the Activity 
(sample-to-sample voltage differences), isoelectric noise, form factor (shape and time 
course of QRS complex) and RR interval. Supplementary Figure 3.2 depicts a typical 
ECG waveform, with the intervals and amplitudes that were measured automatically by the 
software. The data was further cleaned by excluding variables with > 20% difference from 
the median of 6 surrounding beats. To decrease variance, the ECG waveforms were 
averaged over three-minute time intervals during the 20 minutes exposure, and were 
averaged over 5 minutes during the pre- and post-exposure. For HRV, Time and frequency 
domain analysis were performed, at 5 min intervals and the entire 20 minutes during 
exposure, to record root mean square of successive differences (RMSSD) and standard 
deviation of normal beat intervals (SDNN) and LF/HF (ratio of LF to HF power), using the 
spectral settings as per the international guidelines [166].  
Plasma measurements 
The collected blood samples were immediately centrifuged and the plasma fraction 
were frozen until the end of study for batch analysis. The plasma Nicotine, Cotinine and 
Trans-3'-Hydroxy Cotinine in plasma samples were measured by UPLC-MS/MS using a 
Xevo TQ-S micro quadrupole mass spectrometer with an ESI ionization source, interfaced 
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with Waters Acquity Class-H UPLC equipped with a quaternary pump system (Waters, 
MA). Details about the procedure is given in Appendix D. 
Statistical analyses 
Each participant’s absolute change (Δ) for ECG waveforms (intervals and 
amplitudes), and HRV variables were calculated from the pre-exposure (baseline). The 
QTc was calculated by using Bazett formula (QT Interval / √ (RR interval). The Area Under 
the Curve (AUC) for the ECG parameter changes from baseline during exposure (20 
minutes) were calculated using the trapezoidal rule [318] for each participant and as 
average for all participants per study visit. Time series physiologic data are presented as 
change from baseline to allow consistent comparison to reported effects of cigarette, 
nicotine, with and without propranolol. We analyzed time-series deltas (each participant’s 
change during exposure from their own value at baseline) with linear mixed effects models 
(PROC MIXED) for different exposure effects using SAS 9.3 (SAS Systems; Cary, NC). 
A trendline function was also derived for ECG parameter that had significant change from 
Sham, and utilized LINEST function without ‘forced-intercept’ [319], along with six 
different regression types, to find the best fit curve, while maximizing the R-square and 
minimizing the variance to avoid under- and over-fitting. Spearman correlation was used 
to assess the relationship between the Δ in nicotine and its metabolites with the change in 
ECG parameters and Blood Pressure. The potential mediation of effects on ECG 
morphology by acute changes in autonomic balance (measured by RMSSD) was assessed 
by the bootstrapping technique and a macro put forth by Preacher and Hayes [281]. 
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A paired t-test was used to calculate the difference in blood pressure pre and post 
exposure. All statistics with P < 0.05 were considered significant, and were performed in 
SAS 9.3 and Statistical Package for Social Sciences (SPSS) software (version 24, SPSS, 
Inc, Chicago, IL, USA). We also created a typical one-minute ECG waveforms, from pre 
and during exposure, to represent the ECG changes in a Figure, between different 
exposures, using ecgAuto, v3.3 (Emka Technologies, Paris, France). 
Results 
On Cig, NicS and Sham days, the baseline (pre-exposure) ECG parameters, except 
for QTc and JTc, were similar. Pre-treatment with propranolol, decreased the Heart Rate, 
and increased the RMSSD and SDNN and the ST height. There was no significant 
difference in any baseline ECG parameter between BB-Cig and BB-NicS days 
(Supplementary Figure 3.3).  
The AUC for each exposure and study visit along with Sham is shown in Figure 
3.1, while the raw values are shown in Supplementary Figure 3.4.  
Heart Rate and HRV: Cig and NicS both immediately increased heart rate, which 
peaked at minutes 3 to 6 (+20 beats/minute and +14 beats/minute, respectively). After both 
exposures, the heart rate remained elevated up-to 20 minutes and returned to baseline post 
exposure. However, the AUC of heart rate for Cig was higher than that for NicS (p<0.05). 
Pre-treatment with propranolol had a significant impact on HR, with much lower AUC 
observed with BB-Cig vs Cig alone; while there was a non-significant decrease in AUC 
for BB-NicS vs NicS day. Cig  immediately decreased RMSSD (within first 5 minutes and 
lasting for 10 minutes), while NicS had delayed albeit significant and similar decrease in 
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HRV measurements at 10 minutes. The overall significant decrease (vs Sham) in AUC for 
RMSSD was similar between Cig and NicS (P>0.05). Despite RMSSD increased after 
treatment with propranolol on both days, cigarette smoke decreased the RMSSD ( -50 ms) 
vs  Cig day ( -20 ms) (p<0.05); while the AUC for NicS and BB-NicS was similar. Similar 
patterns were observed with SDNN and LF/HF. 
Atrial indices: The smoking and NicS related changes from baseline in P duration 
were not different from those of Sham. However, cigarette use induced immediate and 
significant shortening of PR interval (-14 ms at 9th minute) and PR segment ( -10 ms at 9th 
minute) (P<0.05 vs Sham), and this effect was abolished with pre-treatment with 
propranolol (P > 0.05 vs. Sham), while NicS had no significant impact on PR segment. 
Both, Cig and NicS significantly and similarly increased the P amplitude at 3-6 minutes of 
exposure compared to Sham (+21 µV and +28 µV, respectively), and interestingly this 
effect remained unaltered by propranolol. The AUC of P amplitude for Cig was small 
because, this effect reversed directionality to become negative (though not significantly) at 
9-12 minutes of exposure (i.e. the above zero baseline AUC was similar between Cig and 
NicS). 
Ventricular indices: Cig caused greater shortening of QTc ( -11 ms) relative to NicS 
( -4 ms), and both Cig and Nic significantly shortened QTc relative to Sham (P < 0.05 vs. 
Sham). On BB days, this effect was abolished and the AUC for BB-Cig and BB-NicS were 
similar to Sham, and higher than that of Cig and NicS, respectively. Cig immediately 
shortened QTc in the first 3 min, with a subsequent plateau effect for the remainder of the 
exposure and returning to baseline in the post-exposure period. Cig and NicS similarly 
deepened Q wave amplitude ( -59 µV and -72 µV, respectively, P < 0.05 vs. BL or Sham), 
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with propranolol blocking that effect. There was no significant effect of Cig or NicS on 
QRS and Tp-Te durations. The ST height gradually decreased after Cig and significantly 
differed from Sham minutes 3-6 ( -27 µV), with maximum effect at 9-12 minutes ( -41 µV) 
and slowly subsiding thereafter (remaining significantly decreased at minute 18-21) to 
baseline levels in the post exposure period. NicS had no such effect, and propranolol 
abolished the Cig-induced ST depression. 
The typical 1-minute average ECG morphology during six exposures are shown in 
Figure 3.2. Figure 3.3 shows the best fitting equation for the trendline of the changes in 
Heart Rate, P amplitude, QTc from Cig and NicS and PR segment and ST height from Cig. 
Supplementary Figure 3.4 show the raw and relative of the important ECG parameters 
on different days among smokes.  
Nicotine and its metabolites: The raw and relative changes in nicotine, cotinine and 
3OH were similar among different visit days of smokers; and higher compared to non-
smokers (Supplementary Figure 3.5; p<0.05 for each biomarker). There was significant 
correlation between change in nicotine levels with that of heart rate, ST-height, PR interval, 
PR segment, Q amplitude, SDNN and RMSSD among smokers (Cig and NicS days) and 
non-smokers (Table 3.1).  
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Table 3.1 Correlation between Area under the Curve of ECG parameters with change in 
Nicotine, Cotinine and 3-hyroycotinine (3-OH) among smokers on Cig-Day and NicS-
Day and Non-smokers 
Δ Nicotine Pre-Cotinine Pre-3HC 
Heart Rate 0.443** 0.165 0.099 
ST height -0.299* -0.246 -0.155 
PR interval -0.303* -0.015 0.077 
PR segment -0.318* 0.081 0.135 
P duration 0.015 -0.021 -0.062 
P amplitude 0.123 0.304* 0.219 
QTc interval -0.140 -0.180 -0.084 
QRS duration 0.191 0.128 -0.039 
Q amplitude -0.364** -0.149 0.004 
SDNN -0.344* -0.126 -0.157 
RMSSD -0.446** -0.147 -0.126 
Systolic Blood Pressure 0.438** 0.162 0.148 
Diastolic Blood Pressure 0.374** 0.003 -0.061 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
ANS and other ECG parameters: To test for statistical mediation of the 
electrophysiologic effects of Cig and NicS exposures by ANS imbalance, we also evaluated 
the correlation of RMSSD with the other ECG parameters (Supplementary Table 3.2) 
where only Heart Rate and ST-height correlated with the nicotine levels among smokers 
on Cig-day and non-smokers. Mediation analysis showed that RMSSD completely 
mediated the association of nicotine with ST-height; specifically, the indirect effect (path 
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a x b) of Δ nicotine on ST-height through RMSSD had a point effect estimate (β) of -26.57 
and an upper and lower 95% CI of -82.80 and -0.90. While change in nicotine directly 
affected Heart Rate (c’ path; p=0.036), and this effect was independent of changes in 
RMSSD (Figure 3.4). 
There was no effect of baseline cotinine on the relationship between changes in 
nicotine and that of ECG parameters (Heart Rate, PR segment, ST height and root mean 
squared of successive differences (RMSSD)), among smokers on Cig-Day and NicS-Day 
and Non-smokers (Supplementary Figure 3.6). 
Blood pressure: Both Cig and NicS similarly and significantly increased post-
exposure systolic and diastolic blood pressures relative to Sham and non-smokers 
(Supplementary Figure 3.7). At pre-exposure, blood pressures were similar between Cig, 
NicS and Sham. There was no significant change in blood pressure on the BB days post 
Cig and post NicS. The change in nicotine levels also significantly correlated with the 
changes in blood pressure (Table 3.1), which were not observed on BB days (p>0.05).  
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«: <0.05 vs Sham 
#: <0.05 vs Nicotine 
β: <0.05 vs non- b-blocker 
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«: <0.05 vs Sham 
#: <0.05 vs Nicotine 
β: <0.05 vs non- b-blocker 
Figure 3.1 The Area Under the Curve for the raw changes (Δ) in ECG parameters from 
baseline for each visit day among smokers 
N=20 on Cigarette and NicSpray days. N=10 on sham days 
100 
Sham exposure 
Cigarette exposure Nicotine Spray exposure 
Figure 3.2 ECG morphology in a typical participant during exposure on different days 
Each ECG individual waveform is a 1-minute average before or during exposure to unlit cigarette (sham), cigarette, or nicotine spray. 
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ST height 
PR segment 
Figure 3.3 The best fitting line to predict changes in Heart Rate, P amplitude, and QTc upon Cigarette and Nicotine exposures, and 
additional lines for PR segment and ST height upon Cigarette exposure
N=20  on Cigarette and  NicSpray  days. N=10 on sham days 
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Figure 3.4 Mediation analyses of changes in Nicotine, root mean squared of successive differences (RMSSD) and Heart Rate and ST-
height among smokers on Cig-Day and NicS-Day and Non-smokers 
Nicotine directly and linearly increases the heart rate, independent of pathway involving RMSSD / β-adrenoreceptors. 
RMSSD/ β-adrenoreceptors significantly and fully mediates the effect of smoking on ST height. 
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Discussion 
We have demonstrated in healthy habitual smokers that either smoking one 
cigarette or self-administering 4 mg oral nicotine acutely alters ECG morphology, with 
some key differences between the effects of the two. Moreover, non-selective β-adrenergic 
blockade inhibited many but not all of these effects. These transient ECG changes provide 
a plausible mechanism underlying smoking-induced cardiovascular events, with important 
clinical implications related to recreational use of nicotine delivery products as well. Table 
3.2 summarizes the major findings of the study. 
Table 3.2 Major findings of the experimental study 
None
Abolished
Attenuated
Effect of β-Blocker 
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Sympathetic activation 
Consistent with previous reports, our study found that smoking a single cigarette 
acutely increased heart rate and blood pressure, and decreased HRV and PR segment [90, 
240, 241, 320] – consistent with increased sympathetic activation. The duration of 
increased heart rate up-to 20 minutes, dissipating after 30 minutes, recapitulates 
observations by Ramakrishnan et al, among 31 male smokers with atypical chest pain and 
24 h Holter monitor [238]. However, we showed for the first time that acute nicotine 
exposure causes these changes, with dose-proportionate effects that were diminished by 
propranolol. Nicotine is a known sympathomimetic that acts on nicotinic receptors to 
increase sympathetic tone and catecholamine release. Thus, it is not surprising that we also 
found a dose-proportionate increase in cardiac sympathetic activity from oral nicotine 
administration. Our observations of nicotine-mediated sympatho-excitation add to recent 
literature on the acute physiological effects of nicotine alone [321-323] or within e-
cigarette aerosols [321] and identify a plausible mechanism by which tobacco product use 
increases sympathetic activity.  Indeed, sympathetic dominance strongly predicts 
cardiovascular morbidity and mortality [303, 324, 325], including for arrhythmia-related 
events [326], and can acutely provoke arrhythmia through numerous pathways [327]. 
Importantly, our observations of acute sympathetic dominance with either nicotine oral 
spray or conventional smoking identify nicotine as a plausible mediator of tobacco product-
induced cardiovascular morbidity and mortality. 
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Atria 
P wave morphology is dependent on mainly four factors 1) intra-atrial conduction 
abnormalities, 2) left atrial hypertension, 3) left atrial distention, and 4) chronicity disease 
[328]. Another novel finding of the study was that cigarette smoking and nicotine spray, 
within minutes, increased P wave amplitude, and propranolol prevented these effects. We 
also found non-significant shortening of P duration with cigarette and nicotine use. Both 
these observations are similar those of Goldberg et al., who noted that isoproterenol-
induced β-adrenergic stimulation significantly shortened the P wave in healthy subjects 
[58]. Sympathetic stimulation increases peripheral vascular resistance, venous return and 
cardiac pressures [329], effects also seen with cigarette smoking [330, 331]. Accordingly, 
the significant increase in P amplitude induced by NicS and Cig, and inhibited by β-
blockade, indicate that nicotine increases atrial pressures through β-adrenergic receptors. 
The acute increase in atrial pressures together with increased dromotropy, may represent 
two distinct pathways with possible synergistic effects of tobacco products induced 
increased atrial arrhythmia and thrombosis and stroke risk [283, 312]. 
Ventricles 
To the best of our knowledge, this study demonstrates for the first time that smoking 
acutely induces ST-depression. Smoking caused a gradually worsening ST-depression that 
peaked at 9-12 minutes, abated by about 30 minutes post-exposure, and vanished with 
propranolol pretreatment. Recently, Ramakrishnan noted gross alterations in ST-T 
morphology with smoking (1-2 mm changes in ST segment or T wave), but only in one 
tenth of men with prior atypical chest pain and with onset at 8-12 minutes after smoking 
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[238].   in [238]. The cardio-protective effects of β-blockers among patients with stable 
angina is well described [332]. However, cigarette smoking induced ST-segment 
depression at rest, via β-adrenergic receptors activation complements the propositions of 
others that enhanced sympathetic tone mediates ST-segment depression in general [333-
335]. 
Interestingly, we also found that cigarette smoking caused significant albeit 
minimal shortening of QTc. The relationship between QTc and the ANS is particularly 
complex [299]. However, several studies have shown that acute adrenergic stimulation 
shortens QTc in humans [64, 336], possibly by reducing transmural dispersion of 
repolarization [337]. Chronic smoking is associated with higher potassium levels [338], 
however, acutely it inhibits potassium channels [85] and/or may decrease potassium levels 
via direct sympathetic activation [339]. The effects of potassium levels and/or ion channels 
may be more pronounced in the ventricles than in atria, resulting in hypokalemia related 
ECG changes and ST-segment depression [339]. Unlike the dose-dependent effects of 
nicotine (in either NicS or Cig) on atrial and atrioventricular (AV) electrophysiology, there 
were no significant effects of nicotine on ventricular depolarization and repolarization. We 
speculate this may derive from disproportionate autonomic control of the atria, sinus node, 
and AV node, which have a greater density of cardiac autonomic ganglia than the ventricles 
[340, 341]. Alternatively, because of distinct atrial-specific ion-channel and interceullular 
coupling properties and distribution, atrial myocardium may be more susceptible to 
architectural or structural changes with a substantial impact on cardiac performance, 
arrhythmia occurrence, and stroke risk [342].  
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Strengths and Limitations 
It is well accepted that many of the effects of cigarette smoking, including addiction 
and acute alterations in cardiovascular physiology, stem from the rapid delivery of nicotine. 
However, there are very few studies that have directly compared the effects of nicotine vs 
cigarette, and those studies found no significant effect of nicotine replacement therapy, in 
contrast to cigarette exposure [343], we used a novel oral nicotine spray with 
pharmacokinetic properties for nicotine similar to those of cigarettes [314, 315, 344, 345], 
and also perhaps electronic nicotine delivery systems. We also recorded continuous 
standard 12 lead ECG during exposure, and systematically analyzed the interval and 
amplitudes of each beat with an automated software, to investigate the acute temporal 
relationship of smoking and nicotine exposure on ECG.  
One potential source of variability in this study was the outdoor setting during mid-
exposure ECG monitoring. However, to diminish the influence of outdoor conditions (e.g., 
temperature, humidity, air pollutants etc), most of the study visits were performed on 
consecutive days.  Similarly, we saw no differences in ECG variables between BB and 
non-BB days during the first minute of outdoor recording. To facilitate detection of the 
early acute effects under typical smoking conditions and the delayed acute effects under 
conventional clinical conditions, participants were assessed for ECG changes while seated 
at mid-exposure, but while supine at pre- and post-exposure. We also performed the same 
protocol on 10 healthy non-smokers, where the exposure consisted of periodically inhaling 
through an empty straw for 5 minutes to simulate smoking, and demonstrated that there 
were minor changes related to position. We did not exclude any coronary artery disease 
among the study participants, however, because of our eligibility criteria, participants had 
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no known cardiac medical condition, nor any active symptoms and were healthy. Another 
limitation is that the oral nicotine spray may be pungent and taste unpleasant for some 
participants, which may result in significant changes in heart rate. However, these changes 
are usually transient and less potent than that seen during our study (i.e., increase in heart 
rate of 7.1–13.6% for various taste stimuli, with maximum effect ∼25 s and returned to 
pre-exposure after 80 and 100 seconds [346]. Lastly, since this is a human in vivo 
experimental study, we were unable to differentiate direct vs indirect effects from nicotine 
and cigarette smoking (e.g., heart rate may have increased due to direct effects of nicotine 
and non-nicotine constituents on receptors in the sinoatrial node or central nervous system, 
or instead via reflexes from increased cardiac pressures secondary to increased peripheral 
vascular resistance and systemic pressures). 
Conclusion 
Smoking and nicotine alone acutely induce myriad changes in electrophysiology 
that are known to be pro-arrhythmic. Smoking may acutely promote arrhythmia via 
nicotine-mediated acceleration of heart rate and ventricular repolarization (QTc), with β-
adrenoceptors mediating only the latter. Unlike acute nicotine, cigarette smoke rapidly 
depresses ST segment and shortens PR segment via β-adrenoceptor stimulation, indicating 
smoking transiently induces ischemia and accelerates dromotropy by sympathetic 
activation. Nicotine in cigarette smoke, via β-adrenoceptors, mostly seems responsible for 
transient increase in atrial pressures, which may reflect possible mechanism for tobacco 
induced atrial arrhythmia and stroke risk. 
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CHAPTER IV  
IMPLICATIONS AND CONCLUSIONS 
Clinical Implications 
Cigarette smoking is the most significant modifiable risk factor for cardiovascular 
morbidity and mortality. Although smoking rates in the United States have declined over 
the past five decades to historic lows, efforts to protect public health are far from complete. 
The burden of combustible tobacco use in the United States remains high, especially in 
vulnerable populations. This persistence of cigarette smoking, coupled with the advent and 
dramatic rise in the use of new tobacco products, such as electronic cigarettes, especially 
among adolescents and young adults, are of significant concern [347]. These products may 
benefit by helping some smokers quit or transition to a less harmful product; however, the 
long-term health effects of these products and the net public health effect associated with 
their use remain unclear and widely debated [348]. Evidence is mounting that the use of 
these products may catalyze the transition to the use of other tobacco products or 
recreational drugs, particularly in young adults [349]. The use of certain newly regulated 
tobacco products has skyrocketed, particularly among youths. For example, from 2011 to 
2018, the rate of e-cigarette use among high school students ballooned from 1.5% to 20.8% 
[350], and then up to 27.5% in 2019, according to preliminary results from the Centers for 
Disease Control and Prevention’s annual National Youth Tobacco Survey. 
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Nicotine is addictive and present alongside other chemicals in ENDS. Several 
studies have revealed the existence of toxicants in both the liquid and aerosol of e-
cigarettes. Recent studies suggest that, although adverse experiences such as chest pain, 
palpitations, coronary heart disease, lung injury [351], and increased risk of myocardial 
infarction [352] are associated with e-cigarette use, further investigation is required to 
evaluate whether any causal relationships exist. The FDA has included the discovery of 
biomarkers to assess exposure and harm or toxicity of non-cigarette tobacco products, 
including ENDS, as well the as short- and long-term health effects of tobacco products 
among its research priorities [348]. The series of studies presented in this dissertation 
directly relate to those scientific domains—to help establish sensitive biomarkers to detect 
short-and long-term subclinical cardiovascular injury from tobacco and other nicotine-
related products, and potentially guide regulation of nicotine levels in recreational products 
[347].  
Most investigations into the pharmacokinetics of nicotine from ENDS have yielded 
variable results, perhaps owing to the large variability of study protocols.  Moreover, 
several studies have lacked generalizability, as they incorporated a single standard e-
cigarette and nicotine concentrations with a protocol for vaping at fixed intervals [353]. 
Furthermore, they were unable to investigate the differential impacts of variations in 
experimental parameters, such as battery output voltage or coil resistance, which are known 
to impact delivery of nicotine and production of potentially toxic constituents [354-356]. 
Further complicating the relevance of past ENDS studies, e-cigarette devices have rapidly 
evolved to more effectively deliver nicotine. A recent pharmacokinetic study revealed that 
an ad-lib session with third-generation e-cigarettes is able to achieve the dose and speed of 
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nicotine delivery similar to conventional cigarettes [357]. Another study revealed that 
newer generation e-cigarettes (“mod”-type cigarette) delivered nicotine at levels close to, 
or even exceeding, those of combustible cigarettes (highest average Cmax - 43.6 ng/ml) 
[358].  The parent company of JUUL, the relatively new pod device that has claimed 70%-
80% of the U.S. e-cigarette market [359], noted in their initial patent filing that their device 
achieved 36% higher peak levels of plasma nicotine and higher increases in heart rate with 
more rapid onset than full-flavored cigarettes. This is due in major part to the use of 
nicotine benzoic acid salts, which further enhance nicotine delivery [359]. In our 
experimental trial, the plasma levels were drawn about 45 minutes after the start of 
exposure, and the nicotine levels increased an average of 7.83 ng/ml after cigarette use, 
and 6.98 ng/ml after nicotine spray, which is similar to that achieved by newer e-cigarettes 
[353]. The JUUL brand is one of the newer entries into the market and utilizes prefilled EC 
fluid “pods,” being more similar to the “cig-a-like” products than to the recently available 
tank/box mod styles. Nicotine concentrations (average 60.9 mg/mL) were significantly 
higher in JUUL than those of any EC products previously analyzed by Omaiye et al. [360]. 
Such high nicotine levels are not observed after use of NRTs, with doses recommended to 
reduce withdrawal symptoms and cigarette cravings [344]. Despite the large variability in 
the pharmacokinetic profiles and levels of nicotine due to varying e-cigarette device 
designs, e-liquid concentration, and use behavior, the results of our study provide valuable 
insight into the likely cardiovascular effects and risks of e-cigarettes.  
We conducted three studies that may elucidate the cardiac impacts of nicotine-
containing e-cigarettes. In our cross-sectional observational study, we found that chronic 
nicotine or tobacco exposure leads to dose-dependent shortening of PR segment and QTc, 
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and that an extremely high burden of exposure (measured by the nicotine metabolite, 
cotinine) leads to QRS shortening and JT prolongation. Although our analyses suggested a 
role for nicotine in these effects, the design of this study made it impossible to delineate 
between effects from exposure to cigarette smoke and exposure to nicotine. In our follow-
up acute exposure study, we found evidence that nicotine mediates increased sympathetic 
activity (as measured by decreased HRV), shortened JTc, and increased P amplitude. 
Taking these findings into consideration—and extending to the possible nicotine-related 
effects from ENDS on cardiac electrophysiology—we suggest that e-cigarettes both 
acutely and chronically increase sympathetic activity, as noted in recent observations [321, 
361]. Other studies have also found that conventional smoking chronically increases 
sympathetic modulation of the heart [72, 241]. Moreover, our results suggest that nicotine 
in e-cigarettes may both acutely and chronically shorten ventricular repolarization while 
also acutely increasing atrial pressures (indicated by P amplitude).  Notably, a few studies 
also observed an increased P amplitude among smokers at baseline [212, 213, 362, 363], 
similar to our findings in which cotinine (proxy for tobacco use) was associated with P 
amplitude (particularly in deep terminal negativity of the P wave in V1 [DTNPV1]) in the 
chronic state [364]. However, the mechanisms for abnormal P wave indices during acute 
and chronic exposure may differ while also carrying different prognostic value. As acute 
increases in P amplitude may reflect increased cardiac filling pressure, chronic elevations 
in P amplitude may reflect atrial hypertrophy/distention.  
Such baseline pathophysiological changes in human cardiac electrophysiology 
have clinically important implications. Increases in sympathetic activity [303], atrial 
cardiopathy [365, 366], and shortened rate of ventricular repolarization [367-369] have 
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been associated with increased risk for adverse outcomes, such as all-cause mortality, 
arrhythmia, and stroke. In this regard, a strategy formed by the FDA to limit nicotine levels 
in ENDS might help reduce some of the long-term harmful cardiovascular effects. Our 
study featuring oral nicotine spray indicated that the nicotine levels should be lower than 
those currently found in newer generation e-cigarettes (e.g., JUUL and other pod devices). 
However, more studies are required to establish whether the nicotine levels are directly 
related to increased risk for short- or long-term adverse cardiovascular events.  
Conclusion 
The acute and chronic proarrhythmic effects of smoking and their underlying 
mechanisms are currently unknown. To address this gap in the knowledge, we assessed the 
effects of chronic cigarette exposure on ECG, using serum cotinine (as a sensitive and 
specific marker of tobacco use) from the NHANES database, and urinary cotinine from 
cardiovascular patients from an outpatient clinic. From the NHANES database, higher 
serum cotinine levels were associated with considerably shortened PR intervals, PR 
segments, and QRS duration, and considerably prolonged JT intervals. We also found a 
negative linear relationship between cotinine and QTc, as well as between cotinine and PR 
segment. A similar effect on atrial electrocardiographic indices (shortened PR interval and 
PR segment) was also observed among the CVD patients. Interestingly, our statistical 
mediation analyses indicated that dopamine fully mediated the association between 
cotinine and the shortening of both PR intervals and segments. Collectively, the results 
from the chronic exposure studies suggest that habitual smoking accelerates 
atrioventricular conduction (possibly though dopamine) and ventricular depolarization, but 
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appears to exert a more complex effect on repolarization. Overall habitual smoking 
modestly accelerates ventricular repolarization, and simultaneously increases the risk for 
severe slowing of ventricular repolarization in a subset of patients.  
An experimental trial to investigate β-adrenergic receptors’ role in the acute effects 
of smoking versus nicotine spray on ECG was also performed.  Nicotine, both with and 
without a β-blocker, increases the sympathetic nervous activity to a similar extent as 
observed with cigarette smoking in the presence of a β-blocker. Nicotine increases the heart 
rate through receptors independent of the β-adrenergic receptors, suggesting its acute and 
direct action on cardiomyocytes is independent of increased central sympathetic activation. 
Cigarette smoking had a higher effect on heart rate; however, after treatment with a β-
blocker, the heart rate increase was similar to that from nicotine (with or without a β-
blocker). This suggests that the non-nicotine constituents of cigarette smoke that increase 
heart rate act through β-adrenergic receptors. Cigarette smoking and nicotine comparably 
increase P-wave amplitude without affecting P duration (which was also unaffected in 
chronic exposure studies), and β-blockade did not alter this effect. This increase in P 
amplitude may derive from increased peripheral vascular resistance with both exposures, 
which increases cardiac filling pressures and cardiac output. Cigarette smoking, but not 
nicotine, also shortened the PR segment and decreased the height of the ST segment, with 
both being rescued by β-blockade. This suggests that non-nicotine constituents increase 
dromotropy and ischemia through β-adrenergic receptors. Furthermore, the relationship 
between cotinine and the PR segment found in the chronic exposure studies likely derived 
from cotinine reflecting exposure to tobacco smoke, including non-nicotine constituents.  
Indeed, the tar and nicotine levels in cigarettes correspond with one another, just as 
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exposures to each would be expected to correspond. Consistent with our observations of 
the link between chronic smoking and QTc shortening, ventricular repolarization time was 
more acutely shortened with cigarette smoking compared to nicotine, and was abolished 
by the β-blockade. It is plausible that nicotine acutely accelerates repolarization via 
adrenergic-related mechanisms (e.g., β-adrenergic induced phosphorylation of Kv7.1), 
whereas chronic smoking, itself, impedes repolarization via myocardial injury (e.g., 
fibrosis). Alternatively, chronic smoking may impede repolarization by desensitizing 
adrenergic pathways that would otherwise modulate the heart-rate-dependent shortening 
of repolarization with sympathetic activation in healthy individuals. 
The central illustration combines the findings of all three studies to demonstrate the 
role of nicotine and non-nicotine constituents of cigarette smoke, and the pathways 
involved in their effects on cardiac electrophysiology (Figure 4.1). 
117 
Figure 4.1 Central illustration summarizing the impacts of nicotine and non-nicotine 
constituents of cigarette smoke on cardiac electrophysiology, and the pathways likely 
involved 
Key summary points 
• Of the acute effects of cigarette smoking on ECG, nicotine is partly responsible for
increased sympathetic activity and shortening of ventricular repolarization, but not
for increased dromotropy and ischemia.
• Habitual smoking is associated with increased dromotropy (possibly via
dopamine), faster ventricular depolarization, and inverse J-shaped effects on
ventricular repolarization.
Nicotine alone
β-receptors3
Smoking
(nicotine + aldehydes, PM, hydrocarbons, CO)
↑ heart rate3, 
dromotropy 1,2,3
↓ myocardial 
perfusion3
↑ sympathetic activity3, heart rate3↑ ventricular repolarization rate1,3
Non β-receptors3
Studies
1 NHANES (chronic) 
2 LHHS (chronic)
3 ENSE (acute)
Catecholamines & other neurotransmitters
↑ atrial pressure3
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• Such acute and chronic effects on ECG from cigarette smoking and nicotine may
promote cardiac arrhythmias or reflect a diseased state and an at-risk population.
• Future research is needed to (a) delineate the receptors used by nicotine to cause
sympathetic activation, (b) identify the non-nicotine constituents in cigarette smoke
that transiently increase dromotropy and myocardial ischemia, and (c) elucidate the
mechanisms involved in nicotine and non-nicotine constituents of cigarette-smoke-
induced complex effects on ventricular repolarization (shortening in most patients,
and prolonging in a small subset of patients).
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Supplementary Table 2.1.1 The 5th and 95th percentiles of PR interval, P duration, PR 
segment, corrected QT interval (QTc), QRS durations and uncorrected JT interval 
5th percentile 95
th 
percentile 
PR interval (ms) 126 209 
P duration (ms) 92 134 
PR segment (ms) 22 90 
QTc interval (ms) 359 458 
QRS duration (ms) 80 112 
JT interval (ms) 264 361 
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Supplementary Table 2.1.2 Patient characteristics by PR interval short (<5th percentile), 
reference (5-95th percentile) and long (>95th percentile) groups 
 Characteristic 
PR interval 
p-value 
Short Reference Long 
Age (years) 53.3± 1.0 55.3± 0.4 63.4± 1.3 <0.001 
Women  177 (66.9%) 2698 (54.4%) 125 (48.1%) 0.025 
Non-Hispanic White 136 (84.0%) 2557 (81.6%) 167 (83.8%) 0.467 
Smoking status 
0.051 
Never 114 (41.5%) 2273 (42.0%) 128 (46.2%) 
Current 83 (29.6%) 1172 (23.0%) 42 (12.9%) 
Past 72 (29.0%) 1665 (35.0%) 104 (40.9%) 
Diabetes mellitus  21 (7.2%) 568 (7.3%) 33 (7.2%) 0.986 
Hypertension  73 (21.1%) 1714 (31.0%) 129 (42.7%) <0.001 
Dyslipidemia 63 (23.9%) 1234 (27.7%) 77 (30.5%) 0.399 
Obesity  38 (12.1%) 999 (17.7%) 49 (14.3%) 0.110 
COPD 27 (10.4%) 377 (7.8%) 19 (7.9%) 0.590 
Heart rate (beats/minute) 68.9± 0.9 68.1± 0.3 63.4± 1.3 <0.001 
Prior cardiovascular disease 5 (2.5%) 202 (3.0%) 32 (10.6%) <0.001 
Congestive Heart Failure 5 (1.0%) 159 (1.6%) 21 (5.9%) 0.023 
Alcohol drinks per month 
0 151 (48.0%) 2869 (49.1%) 157 (52.8%) 
0.690 
1-4 44 (18.5%) 826 (17.6%) 53 (19.5%) 
5-13 33 (12.0%) 579 (13.8%) 28 (14.7%) 
>13 40 (21.5%) 824 (19.6%) 34 (12.9%) 
b-blockers 7 (2.4%) 358 (7.4%) 42 (15.8%) <0.001 
Calcium channel blockers 15 (4.6%) 369 (6.0%) 52 (18.5%) <0.001 
Antiarrhythmic drugs  2 (1.6%) 45 (0.8%) 4 (1.4%) 0.591 
Cotinine > 15 ng/ml 93 (36.9%) 1422 (27.6%) 65 (19.9%) 0.026 
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Supplementary Table 2.1.3 Patient characteristics by P duration short (<5th percentile), 
reference (5-95th percentile) and long (>95th percentile) groups 
Characteristic 
P duration 
p-value 
Short Reference Long 
Age (years) 52.5±0.9 55.5±0.4 61.8±1.2 <0.001 
Women 187 (67.1%) 2714 (54.5%) 99 (43.0%) <0.001 
Non-Hispanic White 173 (85.9%) 2547 (81.5%) 140 (82.3%) 0.257 
Smoking status 
0.684 
Never 127 (43.2%) 2275 (42.1%) 113 (41.1%) 
Current 67 (22.2%) 1187 (23.2%) 43 (17.9%) 
Past 83 (34.6%) 1663 (34.7%) 95 (41.0%) 
Diabetes mellitus 23 (5.2%) 568 (7.5%) 31 (7.2%) 0.460 
Hypertension 68 (20.7%) 1732 (31.1%) 116 (45.0%) <0.001 
Dyslipidemia 60 (21.6%) 1255 (27.9%) 59 (29.4%) 0.127 
Obesity 38 (11.5%) 995 (17.5%) 53 (20.9%) 0.057 
COPD 22 (6.6%) 384 (8.1%) 17 (5.4%) 0.346 
Heart rate (beats/minute) 66.2±0.6 68.2±0.3 66.1±1.1 0.009 
Prior cardiovascular disease 6 (2.0%) 209 (3.3%) 24 (5.7%) 0.114 
Congestive Heart Failure 3 (0.2%) 162 (1.8%) 20 (3.9%) 0.021 
Alcohol drinks per month 
0 169 (54.3%) 2867 (48.7%) 141 (52.5%) 
0.156 
1-4 49 (21.4%) 838 (17.7%) 36 (12.4%) 
5-13 26 (10.0%) 586 (14.0%) 28 (11.7%) 
>13 33 (14.2%) 820 (19.5%) 45 (23.4%) 
b-blockers 8 (2.6%) 361 (7.5%) 38 (16.2%) <0.001 
Calcium channel blockers 12 (3.6%) 388 (6.4%) 36 (14.8%) <0.001 
Antiarrhythmic drugs 3 (1.5%) 43 (0.8%) 5 (1.9%) 0.445 
Cotinine > 15 ng/ml 79 (28.6%) 1436 (27.9%) 65 (24.2%) 0.718 
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Supplementary Table 2.1.4 Patient characteristics by PR segment short (<5th percentile), 
reference (5-95th percentile) and long (>95th percentile) groups 
Characteristic 
PR segment 
p-value 
Short Reference Long 
Age (years) 55.6±1.0 55.3± 0.4 60.2±1.4 0.003 
Women  143 (60.8%) 2730 (54.7%) 127 (51.2%) 0.365 
Non-Hispanic White 120 (82.2%) 2575 (81.7%) 165 (84.3%) 0.626 
Smoking status 
0.010 
Never 99 (30.9%) 2299 (42.8%) 117 (40.8%) 
Current 94 (35.6%) 1149 (22.5%) 54 (19.1%) 
Past 79 (33.5%) 1664 (34.7%) 98 (40.1%) 
Diabetes mellitus  27 (8.5%) 563 (7.3%) 32 (6.5%) 0.770 
Hypertension  87 (29.2%) 1704 (30.6%) 125 (40.5%) 0.079 
Dyslipidemia 64 (30.3%) 1241 (27.4%) 69 (28.9%) 0.744 
Obesity  49 (12.1%) 989 (17.7%) 48 (14.2%) 0.139 
COPD 19 (8.2%) 384 (7.8%) 20 (9.2%) 0.823 
Heart rate (beats/minute) 70.5± 0.8 68.1± 0.3 63.6± 0.9 <0.001 
Prior cardiovascular disease 6 (1.9%) 209 (3.1%) 24 (7.4%) 0.022 
Congestive Heart Failure 6 (0.9%) 160 (1.7%) 19 (4.2%) 0.050 
Alcohol drinks per month 
0 140 (39.3%) 2883 (49.7%) 154 (48.7%) 
0.690 
1-4 39 (20.3%) 835 (17.6%) 49 (19.4%) 
5-13 38 (15.6%) 574 (13.6%) 28 (13.5%) 
>13 53 (24.7%) 809 (19.2%) 36 (18.4%) 
b-blockers 15 (3.6%) 350 (7.3%) 42 (15.8%) 0.003 
Calcium channel blockers 14 (4.2%) 375 (6.2%) 47 (15.5%) 0.002 
Antiarrhythmic drugs  2 (0.8%) 47 (0.9%) 2 (0.8%) 0.999 
Cotinine > 15 ng/ml 105 (41.2%) 1399 (27.3%) 76 (24.5%) 0.009 
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Supplementary Table 2.1.5 Patient characteristics by corrected QT short (<5th 
percentile), reference (5-95th percentile) and long (>95th percentile) groups 
 Characteristic 
Corrected QT 
p-value 
Short Reference Long 
Age (years) 55.2±1.0 55.4± 0.4 59.5± 1.0 <0.001 
Women  109 (49.9%) 2725 (54.8%) 166 (58.5%) 0.506 
Non-Hispanic White 125 (80.6%) 2578 (81.8%) 157 (83.3%) 0.722 
Smoking status 
0.443 
Never 104 (39.9%) 2273 (42.0%) 138 (46.7%) 
Current 67 (28.0%) 1178 (22.9%) 52 (18.6%) 
Past 91 (32.1%) 1658 (35.1%) 92 (34.7%) 
Diabetes mellitus  45 (11.3%) 549 (7.1%) 28 (9.0%) 0.226 
Hypertension  102 (31.7%) 1687 (30.5%) 127 (39.2%) 0.131 
Dyslipidemia 67 (28.9%) 1244 (27.7%) 63 (23.6%) 0.473 
Obesity  50 (20.1%) 991 (17.3%) 45 (14.0%) 0.443 
COPD 35 (16.0%) 372 (7.5%) 16 (9.5%) 0.080 
Heart rate (beats/minute) 89.2± 1.0 67.9± 0.2 52.9± 0.6 <0.001 
Prior cardiovascular disease 15 (3.1%) 206 (3.2%) 18 (5.6%) 0.236 
Congestive Heart Failure 15 (3.1%) 152 (1.6%) 18 (3.1%) 0.209 
Alcohol drinks per month 
0 164 (60.8%) 2842 (48.7%) 171 (47.6%) 
0.238 
1-4 36 (17.0%) 841 (18.0%) 46 (14.8%) 
5-13 24 (8.3%) 586 (13.6%) 30 (19.1%) 
>13 37 (13.9%) 828 (19.7%) 33 (18.6%) 
b-blockers 5 (2.7%) 341 (7.1%) 61 (19.2%) <0.001 
Calcium channel blockers 21 (7.5%) 371 (6.1%) 44 (13.2%) 0.005 
Antiarrhythmic drugs  3 (1.0%) 43 (0.8%) 5 (1.5%) 0.627 
Cotinine > 15 ng/ml 85 (32.4%) 1415 (27.5%) 80 (28.4%) 0.531 
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Supplementary Table 2.1.6 Patient characteristics by QRS duration short (<5th 
percentile), reference (5-95th percentile) and long (>95th percentile) groups 
 Characteristic 
QRS duration 
p-value 
Short Reference Long 
Age (years) 56.8± 0.9 55.6± 0.4 53.6± 0.8 0.003 
Women  204 (80.3%) 2726 (55.1%) 70 (22.7%) <0.001 
Non-Hispanic White 144 (78.1%) 2599 (81.8%) 117 (86.1%) 0.223 
Smoking status 
0.197 
Never 128 (44.5%) 2285 (42.1%) 102 (41.3%) 
Current 65 (28.4%) 1163 (22.5%) 69 (25.3%) 
Past 72 (27.0%) 1680 (35.4%) 89 (33.4%) 
Diabetes mellitus  46 (11.5%) 548 (7.1%) 28 (7.3%) 0.205 
Hypertension  91 (34.1%) 1730 (30.9%) 95 (29.9%) 0.704 
Dyslipidemia 72 (30.7%) 1248 (27.5%) 54 (26.4%) 0.684 
Obesity  44 (12.2%) 987 (17.6%) 55 (15.9%) 0.188 
COPD 29 (10.6%) 372 (7.5%) 22 (13.6%) 0.293 
Heart rate (beats/minute) 69.7± 0.9 68.0± 0.2 65.3± 1.1 0.003 
Prior cardiovascular disease 8 (2.1%) 220 (3.3%) 11 (3.7%) 0.566 
Congestive Heart Failure 14 (1.3%) 161 (1.8%) 10 (2.1%) 0.618 
Alcohol drinks per month 
0 176 (61.2%) 2876 (48.9%) 125 (41.2%) 
0.032 
1-4 37 (14.6%) 841 (17.9%) 45 (18.3%) 
5-13 25 (10.2%) 583 (14.0%) 32 (11.0%) 
>13 27 (14.0%) 814 (19.1%) 57 (29.5%) 
b-blockers 12 (4.6%) 376 (7.6%) 19 (8.9%) 0.301 
Calcium channel blockers 20 (5.6%) 396 (6.5%) 20 (7.9%) 0.584 
Antiarrhythmic drugs  1 (0.1%) 45 (0.8%) 5 (2.2%) 0.137 
Cotinine > 15 ng/ml 79 (31.2%) 1416 (27.3%) 85 (33.0%) 0.213 
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Supplementary Table 2.1.7 Patient characteristics by (uncorrected) JT interval short 
(<5th percentile), reference (5-95th percentile) and long (>95th percentile) groups 
 Characteristic 
JT interval 
p-value 
Short Reference Long 
Age (years) 54.5± 1.0 55.3± 0.4 62.0± 0.6 <0.001 
Women  90 (34.5%) 2745 (55.5%) 165 (65.2%) <0.001 
Non-Hispanic White 145 (82.0%) 2554 (81.7%) 161 (83.5%) 0.777 
Smoking status 
0.059 
Never 106 (35.4%) 2267 (42.3%) 142 (46.5%) 
Current 91 (32.4%) 1159 (22.5%) 47 (19.2%) 
Past 107 (32.2%) 1653 (35.1%) 81 (34.3%) 
Diabetes mellitus  52 (11.6%) 540 (6.9%) 30 (10.3%) 0.166 
Hypertension  118 (34.2%) 1679 (30.3%) 119 (40.5%) 0.049 
Dyslipidemia 74 (27.4%) 1242 (27.7%) 58 (26.0%) 0.913 
Obesity  64 (22.6%) 980 (17.1%) 42 (14.6%) 0.246 
COPD 32 (12.2%) 379 (7.7%) 12 (6.2%) 0.118 
Heart rate (beats/minute) 88.0± 0.9 67.5± 0.2 52.5± 0.6 <0.001 
Prior cardiovascular disease 16 (2.8%) 206 (3.1%) 17 (6.6%) 0.107 
Congestive Heart Failure 17 (2.1%) 151 (1.6%) 17 (3.4%) 0.230 
Alcohol drinks per month 
0 174 (57.1%) 2841 (48.6%) 162 (51.8%) 
0.440 
1-4 43 (16.3%) 832 (17.8%) 48 (18.8%) 
5-13 37 (9.9%) 582 (14.1%) 21 (10.3%) 
>13 49 (16.7%) 812 (19.5%) 37 (19.1%) 
Β blockers 7 (2.6%) 344 (7.1%) 56 (21.3%) <0.001 
Calcium channel blockers 20 (5.4%) 373 (6.2%) 43 (14.1%) 0.003 
Antiarrhythmic drugs  4 (1.0%) 44 (0.9%) 3 (0.6%) 0.883 
Cotinine > 15 ng/ml 110 (37.3%) 1391 (27.1%) 79 (31.0%) 0.039 
154 
Supplementary Table 2.1.8 Association between serum cotinine levels (dichotomous) 
and abnormal PR segment, QRS duration and JT interval vs the reference group among 
subgroups by age and sex 
 Subgroups 
PR segment 
<5th percentile vs reference 
QRS duration 
<5th percentile vs reference 
JT interval 
>95th percentile vs 
reference 
Odds ratio 
(95% CI) 
Interaction 
p-value 
Odds ratio 
(95% CI) 
Interaction 
p-value 
Odds ratio 
(95% CI) 
Interaction 
p-value 
Age < 59 
years 
1.92 
(1.08, 3.42) 
0.5661 
1.82 
(1.05, 3.15) 
0.3070 
1.69 
(0.80, 3.58) 
0.4007 
≥ 59 
years 
2.17 
(1.14, 4.13) 
1.22 
(0.76, 1.95) 
1.18 
(0.64, 2.19) 
Sex 
Male 2.26 (1.13, 4.50) 
0.7550 
0.76 
(0.29, 1.96) 
0.0589 
1.49 
(0.72, 3.11) 
0.5171 
Female 1.82 (1.03, 3.20) 
2.03 
(1.37, 3.00) 
1.74 
(0.92, 3.31) 
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Supplementary Figure 2.2.1 Flowchart of selection of participants for study analysis 
164 ECGs available in 
Louisville Healthy 
Heart Study
153
ECGs read
136 
patients included in study
Excluded=16;
Urinary nicotine and catecholamines 
levels not available
Excluded=12
4 Atrial fibrillation, 3 
Atrial flutter, 4 Paced
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Appendix A 
ECG Measurement protocol for LHHS database 
Exclude ECGs with Atrial fibrillation, Atrial flutter, paced rhythm. 
The caliper measurements will be performed using electronic calipers and recorded up to 
2 decimal points. Only waveforms in sinus rhythm will be included and measurements will 
be performed only on segments those are completely captured in that lead (ie complete 
QRS can be visualized in V6 and not QRS starting from V3 and transitioning into V6). 
Each segment will be measured and recorded in three consecutive waveforms. 
Incompletely recorded beats, premature atrial and ventricular beats will be excluded and 
the next complete sinus waveform in sequential order will be measured.  
P wave duration 
P wave duration will be measured in lead II. Measurement will be conducted from the onset 
of the P wave, defined as the initial deflection from the isoelectric baseline of the TP 
segment, to the offset of the P wave, defined as the return of the P wave to the isoelectric 
baseline of the PR interval.  
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P wave amplitude 
P wave amplitude will be measured in lead II. Measurement from the onset of the P wave 
to its highest amplitude. Use previous T-P segment as baseline (end of T-wave to beginning 
of P-wave). 
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PR wave duration 
PR duration will be measured in lead II. The PR interval was measured from the onset of 
the P wave to the onset of the QRS complex, defined as the initial deflection from the 
baseline of the PR interval.  
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QT interval 
The QT interval was measured in lead V5, and determined as the onset of the QRS complex 
to the end of the T wave; defined as the return of the T wave to the isoelectric baseline of 
the TP segment.  
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QRS duration 
QRS duration was measured in lead V6, and determined as the onset of the QRS complex 
to the return of the complex to the isoelectric baseline of the ST segment. If in doubt 
regarding the isoelectric segment, use previous T-P segment as baseline (end of T-wave to 
beginning of P-wave).  
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In cases when it is hard to identify the end of QRS because ST segment is sloped and/or 
QRS is wide and complex then tangent line method as below can be used: when the tracing 
becomes more horizontal than vertical. 
When in doubt or when two J points are visualized then the earlier J point should be used 
to measure QRS duration. 
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T wave amplitude 
T wave amplitude will be measured in lead V5. Measurement from the onset of the T wave 
to its highest amplitude. In case of predominant negative T wave where the highest 
deflection is below the baseline then add a comment on the side and measure the amplitude 
from baseline to most lowest amplitude. 
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T peak – T end 
T wave amplitude will be measured in lead V5. Measurement will be conducted peak of 
T-wave to the offset of the T wave, defined as the return of the T wave to the isoelectric 
baseline (TP segment as described above). 
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In cases when it is hard to identify the end of T then tangent line method as below can be 
used.  
R-R intervals 
Use the lead which has the longest continuous ECG recording, which is usually at the 
bottom of the ECG sheet. Use preferably Lead II if available otherwise use V1. Measure 
the duration between all R-R intervals. If R is not present then use any identical points on 
consecutive EKG waveforms such as the Q-Q or P-P duration. Do not measure R-R 
between sinus and a premature atrial or ventricular beat (defined as beat occurring 20% 
earlier to previous interval) and measure the subsequent waveforms. 
165 
References for ECG Measurement protocol 
Prineas RJ, Crow RS Zhang ZM. The Minnesota Code Manual of Electrocardiographic 
Findings. 2nd Edition, London: Springer, 2010. 
Jacob Melgaard et al. Automatic J-point Location in Subjects with Electrocardiographic 
Early Repolarization Computing in Cardiology 2014; 41:585-588 
Considerations about the polemic J point location 
http://bscw.rediris.es/pub/bscw.cgi/d5046031/CONSIDERACIONES%20ACERCA%20
DE%20LA%20LOCALIZACI%C3%93N%20POL%C3%89MICA%20DEL%20
PUNTO%20J.pdf 
Burke GM et al. J Electrocardiol. 2014 May-Jun;47(3):288-93. doi: 
10.1016/j.jelectrocard.2014.01.004. Epub 2014 Jan 6. Assessment of 
reproducibility--automated and digital caliper ECG measurement in the 
Framingham Heart Study.  
Tarek MohamedAbdelrahman The Egyptian Journal of Critical Care Medicine Volume 2, 
Issue 1, April 2014, Pages 19-27. Prognostic value of T peak-to-end interval for 
risk stratification after acute myocardial infarction 
Erikssen G et al. Ann Noninvasive Electrocardiol. 2012 Apr;17(2):85-94. doi: 
10.1111/j.1542-474X.2012.00493.x. The terminal part of the QT interval (T peak 
to T end): a predictor of mortality after acute myocardial infarction. 
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Supplementary Table 2.2.1 Baseline characteristics by high and low PR interval, P wave duration and PR segment 
PR interval P-wave duration PR segment 
≤ 163.32 
ms 
> 163.33+ 
ms p value 
≤ 104.73
ms 
> 104.74 
ms p value 
≤ 55.20
ms 
> 55.21 
ms p value 
Age (years)* 49, 11 55, 8 0.01 51, 11 54, 8 0.11 51, 10 53, 9 0.18 
BMI (kg/m2)* 31, 7 34, 9 0.07 31, 7 35, 8 0.01 32, 7 34, 9 0.10 
SBP (mm Hg)* 133, 21 134, 25 0.95 129, 21 138, 25 0.07 135, 22 132, 24 0.13 
DBP (mm Hg)* 80, 10 81, 15 0.52 78, 12 84, 14 0.05 82, 11 79, 15 0.16 
Heart rate (beats/min)* 75, 17 71, 13 0.27 73, 16 73, 13 0.53 75, 16 72, 14 0.28 
Male gender 27, 42% 45, 63% 0.01 31, 44% 41, 64% 0.02 33, 52% 39, 55% 0.70 
Caucasian 37, 58% 40, 56% 0.86 44, 62% 33, 52% 0.22 39, 61% 38, 54% 0.39 
Hypertension 54, 84% 64, 90% 0.31 57, 80% 61, 95% 0.01 55, 86% 63, 89% 0.63 
Prior MI 26, 41% 36, 51% 0.24 31, 44% 31, 48% 0.58 32, 50% 30, 42% 0.37 
Diabetes 18, 28% 25, 35% 0.38 20, 28% 23, 36% 0.33 17, 27% 26, 37% 0.21 
Stroke 13, 20% 10, 14% 0.34 15, 21% 8, 13% 0.18 10, 16% 13, 18% 0.68 
Arrhythmia 22, 34% 23, 32% 0.81 25, 35% 20, 31% 0.63 20, 31% 25, 35% 0.63 
Β blocker 43, 67% 55, 78% 0.18 51, 72% 47, 73% 0.83 42, 66% 56, 79% 0.09 
CCB 13, 20% 19, 27% 0.38 10, 14% 22, 34% 0.01 13, 20% 19, 27% 0.38 
ACEI or ARB 38, 59% 51, 72% 0.13 39, 55% 50, 78% 0.01 44, 69% 45, 63% 0.51 
Statin 41, 64% 43, 61% 0.68 45, 63% 39, 61% 0.77 41, 64% 43, 61% 0.68 
Aspirin 35, 55% 46, 65% 0.23 43, 61% 38, 59% 0.89 34, 53% 47, 66% 0.12 
Diuretics 24, 38% 34, 48% 0.22 26, 37% 32, 50% 0.12 21, 33% 37, 52% 0.02 
Abbreviations: BMI - Body mass index, SBP- Systolic Blood Pressure, DBP – Diastolic Blood Pressure, MI – Myocardial Infarction, CCB – Calcium Channel 
Blocker, ACE - Angiotensin-Converting Enzyme Inhibitor, ARB - Angiotensin II Receptor Blocker.   
For each variable counts and column percentage has been reported except for where indicated * where the mean and standard deviation (SD) are reported 
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Supplementary Table 2.2.2 Distribution of urinary cotinine levels by self-reported active smoking status among all participants 
Smoking status 
Cotinine 
≤ 50 ng/ml 
(N=73, 54%) 
> 50 ng/ml 
(N=63, 46%) 
Current smoker (53, 39%) 2, 3% 51, 81% 
Former smoker (47, 35%) 38, 52% 9, 14% 
Never smoker (36, 26%) 33, 45 % 3, 5% 
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Supplementary Table 2.2.3 Comparison among participants stratified by self-reported smoking status or by cotinine level of (A) 
urinary cotinine and catecholamines (median [interquartile range], creatinine-normalized), and (B) high and low PR interval, P wave 
duration and PR segment 
(A) 
Cotinine 
(ng/g) 
Dopamine 
(μg/g) 
Epinephrine 
(μg/g) 
Norepinephrine 
(μg/g) 
p 
value 
p 
value 
p 
value 
p 
value 
Smoking 
status 
Active 
smoker 
827.1 
[527.3 - 1445.3] <0.001
176.0 
[146.5 - 225.8] 0.24
5.7 
[3.3 - 10.8] 0.31 
42.5 
[30.7 - 60.3] 0.07
Former-
smoker* 
3.7 
[1.3 - 18.9] - 
167.1 
[135.6 - 204.9] - 
4.2 
[2.6 - 8.5] - 
36.2 
[26.4 - 51.4] - 
Never 
smoker 
1.6 
[0.9 - 4.0] <0.001 
139.7 
[114.3 - 169.7] 0.001
3.7 
[1.5 - 6.5] 0.03 
32.4 
[19.0 - 49.2] 0.02
Cotinine 
≤ 50 ng/ml 1.8 [1.0 - 4.2] <0.001 
160.0 
[ 112.4 - 189.1] 0.003
4.1 
[2.1 - 6.9] 0.08 
33.4 
[22.7 - 50.6] 0.02
> 50 ng/ml 827.1 [522.8 - 1596.0] 
175.8 
[142.0 - 227.9] 
5.9 
[3.1 - 9.2] 
42.5 
[30.4 - 56.4] 
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(B) 
PR interval P wave duration PR segment 
≤ 163.32 ms > 163.33 ms p value ≤ 104.73 ms 104.74 ms 
p 
value ≤ 55.20 ms 55.21 ms
p 
value 
Smoking 
status 
Current 
smoker 25, 39% 28, 39% 
0.76 
34, 48% 19, 30% 
0.08 
26, 40% 27, 38% 
0.58 Former smoker 24, 38% 23, 32% 20, 28% 27, 42% 24, 38% 23, 32% 
Never 
smoker 15, 23% 20, 28% 17, 24% 18, 28% 14, 22% 21, 30% 
Cotinine 
≤ 50 ng/ml 34, 53% 38, 54% 
0.96 
34, 48% 38, 59% 
0.18 
32, 50% 40, 56% 
0.49 
> 50 ng/ml 30, 47% 33, 46% 37, 52% 26, 41% 32, 50% 31, 44% 
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Supplementary Table 2.2.4 Association between creatinine-normalized log transformed cotinine and parent catecholamines, their 
intermediate and final metabolites, and their metabolism, denoted by the ratios of intermediate: parent and final: intermediate 
metabolites 
Parent Intermediate Intermediate / Parent Final Final / Intermediate 
b p value b p value b p value b p value b p value 
Cotinine 
DA 0.25 <0.01 0.36 <0.01 0.19 0.03 -0.01 0.95 -0.37 <0.01 
NE 0.22 0.01 019 0.03 -0.06 0.47 -0.14 0.11 -0.28 <0.01 
EP 0.11 0.19 0.37 <0.01 0.10 0.27 -0.14 0.11 -0.37 <0.01 
   Parent Intermediate Final 
DA: Dopamine 3-methoxytyramine Homovanillic acid 
NE: Norepinephrine Normetanephrine Vanillylmandelic acid 
EP: Epinephrine Metanephrine  Vanillylmandelic acid 
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Supplementary Table 2.2.5 Associations of QRS duration, QT interval and corrected QT with urinary cotinine in unadjusted and 
adjusted linear regressions 
Urinary cotinine was normalized by urine creatinine and log-transformed 
QRS QT Corrected QT 
b p value b p value b p value 
Unadjusted Cotinine 0.32 0.80 4.71 0.11 3.48 0.14 
*Adjusted Cotinine -0.34 0.78 3.33 0.78 0.11 0.13 
* models adjusted for diastolic blood pressure and prior myocardial infarction (QRS); age, heart rate, systolic blood pressure, and calcium channel blocker (QT);
age (QTc) 
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Supplementary Table 2.2.6 Association between catecholamine and atrial or atrioventricular conduction determined by unadjusted 
and adjusted linear regressions 
Catecholamines were creatinine-normalized and log-transformed 
PR interval P wave PR segment 
b p value b p value b p value 
Unadjusted 
Dopamine -17.13 <0.01 -8.45 <0.01 -8.68 0.04 
Epinephrine -5.47 0.02 -2.8 0.04 -2.66 0.16 
Norepinephrine -7.31 0.11 -4.79 0.08 -2.52 0.49 
*Adjusted
Dopamine -12.3 0.02 -3.56 0.28 -8.51 0.04 
Epinephrine -6.62 <0.01 -2.73 0.06 -2.53 0.19 
Norepinephrine -10.16 0.02 -3.39 0.18 -2.69 0.46 
* models adjust for age and gender (PR interval); body mass index, gender, hypertension, calcium channel blocker, ACE-inhibitor or angiotensin II receptor
blocker (P duration); and diuretics (PR segment) 
173 
Supplementary Table 3.1 Baseline characteristics 
Smoker ID Age Gender Race Body Mass Index 
b-Blocker 
protocol 
Sham- 
protocol 
Pack-
Years Cigarette brand
Nicotine 
content (mg) 
1 26 Male White 31 Yes Yes 9 L&M 0.8 
2 28 Male Black 29 Yes - 36 L&M 0.9 
3 23 Female Black 29 Yes Yes 5 L&M 0.9 
4 32 Male Black 23 - Yes 29 Newport 0.8 
5 31 Male White 37 - - 15 Marlboro 1.1 
6 39 Female White 25 - - 22 Pall Mall 0.9 
7 23 Male White 24 Yes Yes 7 L&M 0.9 
8 22 Male Black 22 - - 6 L&M  0.8 
9 25 Male White 24 - - 7 Camel 0.8 
10 25 Female White 30 - - 11 USA Gold Reds 0.8 
11 52 Male White 25 Yes - 22 High Card  0.8 
12 42 Female White 29 Yes Yes 60 High Card 0.8 
13 53 Female White 34 Yes - 42 Pall Mall 1.1 
14 43 Male White 30 Yes - 18 American Spirit 0.6 
15 49 Female Other 21 Yes - 35 High Card 0.8 
16 62 Male Black 28 Yes Yes 20 Newport  0.8 
17 61 Male White 21 - Yes 48 Kool  0.6 
18 39 Male White 26 - Yes 25 Marlboro 1.0 
19 43 Female White 32 - Yes 29 Camel 1.0 
20 28 Male Other 34 - Yes 14 Pall Mall 0.9 
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Supplementary Table 3.2 Correlation between Area under the Curve of root mean squared of successive differences (RMSSD) and 
rest of ECG waveform parameters 
Cigarette-Days and 
Non-smokers 
N=29 
Cigarette-Days,  
Nicotine Days  
and Non-smokers 
N=49 
Heart Rate -0.459** -0.436** 
ST height 0.430* 0.225 
PR interval -0.004 0.184 
PR segment 0.164 0.026 
P duration -0.109 0.190 
P amplitude 0.076 0.174 
QTc interval 0.192 -0.002 
QRS duration -0.384 -0.217 
Q amplitude 0.462 0.213 
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A)
176 
(B) 
Supplementary Figure 3.1 A) Flow chart to show the study design and enrollment B) Schematic Figure to illustrate the study visit 
procedures on different days 
177 
Supplementary Figure 3.2 ECG morphological variables measured from Lead II 
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«: <0.05 vs Sham
#: <0.05 vs Nicotine
β: <0.05 vs non-Beta-blocker 
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«: <0.05 vs Sham
#: <0.05 vs Nicotine
β: <0.05 vs non-Beta-blocker 
Supplementary Figure 3.3 The Area Under the Curve for the baseline ECG parameters 
for each visit day among smokers 
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Supplementary Figure 3.4 The raw values of several ECG parameters in pre-post and during exposure days among smokers 
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Δ Δ%
Supplementary Figure 3.5 The raw (Δ) and relative (Δ%) changes with standard errors of nicotine, Cotinine and 3-hyroycotinine (3-
OH) levels from baseline per study visit 
Difference between pre and post exposure:
Nicotine 
Cotinine 
3HC (3-hyoxycotinine) 
 Cig  NicS  BB-Cig  BB-NicS     Non-Smoker 
 Cig  NicS        BB-Cig       BB-NicS     Non-Smoker 
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Supplementary Figure 3.6 The relationship between Area Under the Curves (AUC) of ECG parameters (Heart Rate, PR segment, ST 
height and root mean squared of successive differences (RMSSD)), with changes in Nicotine and Baseline Cotinine levels 
X axis - Δ Nicotine  (ng/ml) 
Y axis – AUC of Δ ECG parameter 
Z axis – Relative size of bubble indicates baseline cotinine level 
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(A) 
Supplementary Figure 3.7 The changes in Blood Pressure post cigarette and Nicotine 
Spray use (A) and their correlation with change in nicotine levels (B) 
There is no significant difference in pre-exposure and post exposure Blood pressure 
between Cig and NicS days (p>0.05).  
(B) 
20 smokers (Cig-day 
and NicS-day) and 
9 non-smokers 
β-Blocker Cigarette and 
β-Blocker Nicotine days 
N=20 
Systolic Blood Pressure 0.438 P = 0.001 
0.180 
P = 0.447 
Diastolic Blood Pressure 0.374 P =0.008 
-0.160 
P =0.500 
«: <0.05 vs Pre-exposure
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Appendix B 
Visit:  Day 1 □ or Day 2 □
Subject ID:______________    DOB: ___________ Outside Temp:_______ Humidity: ________ 
Date:__ __/__ __/ __ __  Time of arrival: _____:_____  
Consent / abstained from food / beverages (Except water) for 8 hours and from nicotine/Cig for 8 
hours? Y/N 
Date and time for last Cigarette/E-cig or other nicotine product use: Date:__ __/__ __ / __ __ 
Time:_____:_____  Height _____________Weight_____________  
Record START time for each event 
Rest 5 mins 
(consent) 
BP and HR 
(sitting) 
Rest 5 mins 
(reclining) 
ECG 
12 sec and 
5 mins 
IV blood draw Walk outside 
and rest 5 
mins 
(sitting) 
Start ECG 
after rest 
Smoke/ 
Nicotine/ Straw 
outside 
(sitting) 
Record 20 
mins ECG 
outside 
including the 
exposure time 
(sitting) 
Walk 
inside 
1. 
Time:___:___ 
SBP______ 
DBP______ 
HR______ 
2. 
Time:___:___ 
3. 
Time:___:___ 
Plasma 
C:___:___ 
S:___:___ 
Serum 
C:___:___ 
S:___:___ 
4. 
Time:___:___ 
5. 
Start 
Time:___:___ 
Stop 
Time:___:___ 
□Cigarette
□Nicotine
□Straw
6. 
Time:___:___ 
7. 
Time:__
_:___ 
Rest 5 mins 
(reclining) 
ECG 
12 sec and 
5 mins 
Rest 5 mins 
(questionnaire) 
BP and HR 
(sitting) 
IV blood draw Time of 
departure 
2. 
Time:___:___ 
2. 
Time:___:___ 
SBP______ 
DBP______ 
HR______ 
3. 
Time:___:___ 
Plasma 
C:___:___ 
S:___:___ 
Serum 
C:___:___ 
S:___:___ 
7. 
Time:___:___ 
Recorded by:______________________________________________ Date:__ __/__ __/ __ __ 
PI Signature:_______________________________________________ Date:__ __/__ __/ __ __ 
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Visit:  Day 3 □ or Day 4 □
Subject ID:______________    DOB: ___________  Outside Temp:_______ Humidity: 
________ 
Date:__ __/__ __/ __ __  Time of arrival: _____:_____   
Consent / abstained from food / beverages (Except water) for 8 hours and from nicotine/Cig for 8 
hours? Y/N 
Date and time for last Cigarette/E-cig or other nicotine product use: Date:__ __/__ __ / __ __ 
Time:_____:_____  Height _____________Weight_____________   
100 mg propranolol ______:_______ 
BP and HR every 15 mins for 2 hours 
Rest 5 mins 
(consent) 
BP and HR 
(sitting) 
Rest 5 mins 
(reclining) 
ECG 
12 sec and 
5 mins 
IV blood draw Walk outside 
and rest 5 
mins 
(sitting) 
Start ECG 
after rest 
Smoke/ 
Nicotine/ Straw 
outside 
(sitting) 
Record 20 
mins ECG 
outside 
including the 
exposure time 
(sitting) 
Walk 
inside 
1. 
Time:___:___ 
SBP______ 
DBP______ 
HR______ 
2. 
Time:___:___ 
3. 
Time:___:___ 
Plasma 
C:___:___ 
S:___:___ 
Serum 
C:___:___ 
S:___:___ 
4. 
Time:___:___ 
5. 
Start 
Time:___:___ 
Stop 
Time:___:___ 
□Cigarette
□Nicotine
□Straw
6. 
Time:___:___ 
7. 
Time:__
_:___ 
Rest 5 mins 
(reclining) 
ECG 
12 sec and 
5 mins 
Rest 5 mins 
(questionnaire) 
BP and HR 
(sitting) 
IV blood draw Time of 
departure 
2. 
Time:___:___ 
2. 
Time:___:___ 
SBP______ 
DBP______ 
HR______ 
3. 
Time:___:___ 
Plasma 
C:___:___ 
S:___:___ 
Serum 
C:___:___ 
S:___:___ 
7. 
Time:___:___ 
Recorded by:_______________________________________________Date:__ __/__ __/ __ __  
PI Signature:________________________________________________Date:__ __/__ __/ __ __ 
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Appendix C 
Protocol on how to use LabChart for ECG measurements 
1. Open file
2. Uncheck the “Times in first Column”
3. Set the default sampling rate to 500 Hz
4. Click OK
5. Autoscale all channels
6. Analyze the entire ECG and search and record any arrhythmia, blocks, ectopic beats
(PACs, PVCs) Quantify ectopic beats and time relative to exposure. Confirm QRS
complex is within 80 ms.
7. Click ECG settings
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8. Click ECG Beat Classifier View
Select 
Channel 
Change to 
time and 
select 60 s 
Select 
Framingham 
Other 
settings 
kept as 
default 
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Exclude the outlier beats by mapping the case-specific distribution of activity over the 
isoelectric noise (in millivolts) and the distribution of the form factor over the RR interval 
(in seconds). 
Click on the marked point and view the beat to decide whether to exclude or not. If 
excluded then go to the next outlier closer to the data and decide about its inclusion. Keep 
repeating it until you find a beat which is normal and should be included. Perform this at 
each four quadrants and using both; Form Factor and Activity.  
9. Scroll the entire ECG recording and ensure that all selected beats should be included
in the analysis
10. Click ECG Table View
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Appendix D 
Nicotine and metabolites determination in human plasma 
2.1. Chemicals and reagents 
(−)-Nicotine (NIC), (-)-Cotinine (COT), and LC-MS Ultra grade ammonium formate were 
purchased from Sigma-Aldrich (St. Louis, MO). Trans-3'-Hydroxy Cotinine (3HC), and 
trans-3'-Hydroxy Cotinine-d3 (3HC-d3) were purchased from Toronto Research Chemicals, 
(Toronto, Canada). (±)-Nicotine-d3 (NIC-d3) and (±)-Cotinine-d3 (COT-d3), were 
purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada). UHPLC-MS grade water, 
UHPLC-MS grade acetonitrile, and LC-MS grade formic acid were purchased from 
Thermo Fisher Scientific Inc. (Waltham MA). 
2.2. UPLC-MS/MS analysis 
NIC, COT, and 3HC in human plasma samples were measured by UPLC-MS/MS using a 
Xevo TQ-S micro quadrupole mass spectrometer with an ESI ionization source, interfaced 
with Waters Acquity Class-H UPLC equipped with a quaternary pump system (Waters, 
MA). 
After the sample was thawed on ice, 20 μl of plasma was mixed with 480 μl of 75% 
acetonitrile with isotopic labeled internal standard (COT-d3, NIC-d3, and 3HC-d3) in a 1.7 
ml microcentrifuge tube. After incubation on ice for 30 min, the mixture was centrifuged 
at 4°C for 30 min, and 2 μl of the supernatant was applied on the UPLC-MS/MS instrument. 
The separation was performed on an Acquity UPLC BEH HILIC (50 mm × 2.1 mm, 1.7 
μm) column (Waters, MA) with a binary gradient comprised of 95% water 5% ACN 10mM 
ammonium formate pH 3 (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) at 
a flow rate 0.4 ml/min. The gradient started at 96.5% for 1.2 min, ramped down to 30% 
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solvent B over a 3 min period. Then the gradient ramped down to 0% B in 0.1 min, held at 
0% B for 0.3 min, return to 96.5% B in 0.1 min, and held for 5.3 min until next injection. 
Chromatography was performed at 40 °C. The total chromatographic run time was 10 min. 
The mass spectrometry detector worked in positive ion mode. Optimized cone voltage and 
collision energy were used for each of the individual analytes. For each analyte, three 
multiple reaction monitoring (MRM) transitions were set up: one for quantification, one 
for confirmation, and one for labeled internal standard. Transitions for NIC are 163 > 130 
for quantification, 163 > 117 for confirmation, and 166 > 130 for internal standard (NIC-
d3). Transitions for COT are 177 > 80 for quantification, 177 > 98 for confirmation, and 
180 > 80 for internal standard (COT-d3). Transitions for 3HC are 193 > 80 for 
quantification, 193 > 134 for confirmation, and 196 > 80 for internal standard (3HC-d3). 
These MRMs were scheduled around the retention time of the analytes. No less than 15 
data points were collected for each peak. 
TargetLynx quantification application manager software (Waters, MA) was used for peak 
integration, calibration, and quantification. Analytes in plasma samples were quantified 
using peak area ratio based on a 7 point-standard curves which were run before and after 
the plasma samples. 
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